<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article
  PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">JOP</journal-id>
<journal-id journal-id-type="hwp">spjop</journal-id>
<journal-id journal-id-type="nlm-ta">J Psychopharmacol</journal-id>
<journal-title>Journal of Psychopharmacology</journal-title>
<issn pub-type="ppub">0269-8811</issn>
<issn pub-type="epub">1461-7285</issn>
<publisher>
<publisher-name>SAGE Publications</publisher-name>
<publisher-loc>Sage UK: London, England</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.1177/0269881111431750</article-id>
<article-id pub-id-type="publisher-id">10.1177_0269881111431750</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Original Papers</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Pharmacokinetics and central nervous system effects of the novel dopamine D<sub>3</sub> receptor antagonist GSK598809 and intravenous alcohol infusion at pseudo-steady state</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author" corresp="yes">
<name><surname>te Beek</surname><given-names>ET</given-names></name>
<xref ref-type="aff" rid="aff1-0269881111431750">1</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Zoethout</surname><given-names>RWM</given-names></name>
<xref ref-type="aff" rid="aff1-0269881111431750">1</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Bani</surname><given-names>MSG</given-names></name>
<xref ref-type="aff" rid="aff2-0269881111431750">2</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Andorn</surname><given-names>A</given-names></name>
<xref ref-type="aff" rid="aff2-0269881111431750">2</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Iavarone</surname><given-names>L</given-names></name>
<xref ref-type="aff" rid="aff2-0269881111431750">2</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Klaassen</surname><given-names>ES</given-names></name>
<xref ref-type="aff" rid="aff1-0269881111431750">1</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Fina</surname><given-names>P</given-names></name>
<xref ref-type="aff" rid="aff2-0269881111431750">2</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>van Gerven</surname><given-names>JMA</given-names></name>
<xref ref-type="aff" rid="aff1-0269881111431750">1</xref>
</contrib>
</contrib-group>
<aff id="aff1-0269881111431750"><label>1</label>Centre for Human Drug Research, Leiden, the Netherlands</aff>
<aff id="aff2-0269881111431750"><label>2</label>Neurosciences CEDD, GlaxoSmithKline Research &amp; Development Limited, Verona, Italy</aff>
<author-notes>
<corresp id="corresp1-0269881111431750">Erik T te Beek, Centre for Human Drug Research, Zernikedreef 10, 2333 CL Leiden, the Netherlands Email: <email>etbeek@chdr.nl</email></corresp>
</author-notes>
<pub-date pub-type="epub-ppub">
<month>2</month>
<year>2012</year>
</pub-date>
<volume>26</volume>
<issue>2</issue>
<fpage>303</fpage>
<lpage>314</lpage>
<permissions>
<copyright-statement>© British Association for Psychopharmacology 2012</copyright-statement>
<copyright-year>2012</copyright-year>
<copyright-holder content-type="sage">British Association for Psychopharmacology</copyright-holder>
</permissions>
<abstract>
<p>GSK598809 is a novel selective dopamine D<sub>3</sub> receptor antagonist, currently in development for the treatment of substance abuse and addiction. In a blinded, randomized, placebo-controlled study, effects of single oral doses of 175 mg GSK598809 were evaluated in healthy volunteers. Pharmacokinetics, central nervous system (CNS) effects and potential for interactions with alcohol were evaluated, using an alcohol infusion paradigm and analysis of eye movements, adaptive tracking, visual analogue scales, body sway, serum prolactin and verbal visual learning test. Adverse effects of GSK598809 included headache, dizziness and somnolence. Plasma concentration of GSK598809 was maximal 2–3 hours postdose and decreased with a half-life of roughly 20 hours. CNS effects were limited to prolactin elevation and decreased adaptive tracking. Co-administration of GSK598809 and alcohol did not affect alcohol pharmacokinetics, but caused a 9% decrease of <italic>C</italic><sub>max</sub> and a 15% increase of AUC of GSK598809. CNS effects of co-administration were mainly additive, except a small supra-additive increase in saccadic reaction time and decrease in delayed word recall. In conclusion, GSK598809 causes elevation of serum prolactin and a small decrease in adaptive tracking performance. After co-administration with alcohol, effects of GSK598809 are mainly additive and the combination is well tolerated in healthy volunteers.</p>
</abstract>
<kwd-group>
<kwd>Addiction</kwd>
<kwd>alcohol</kwd>
<kwd>dopamine D3 receptor</kwd>
<kwd>GSK598809</kwd>
<kwd>interaction</kwd>
<kwd>pharmacodynamics</kwd>
<kwd>pharmacokinetics</kwd>
<kwd>substance abuse</kwd>
</kwd-group>
</article-meta>
</front>
<body>
<sec id="section1-0269881111431750" sec-type="intro">
<title>Introduction</title>
<p>A large body of evidence indicates that the mesolimbic dopaminergic pathway, which includes dopaminergic neurons in the ventral tegmental area projecting to the nucleus accumbens and other limbic forebrain structures, is one of the major neuronal circuits involved in the acute rewarding effects of drugs of abuse (<xref ref-type="bibr" rid="bibr26-0269881111431750">Koob and Nestler, 1997</xref>; <xref ref-type="bibr" rid="bibr27-0269881111431750">Koob et al., 1998</xref>; <xref ref-type="bibr" rid="bibr22-0269881111431750">Hyman and Malenka, 2001</xref>; <xref ref-type="bibr" rid="bibr11-0269881111431750">Cami and Farre, 2003</xref>; <xref ref-type="bibr" rid="bibr21-0269881111431750">Hyman, 2005</xref>). Although addictive drugs interact with many different neurotransmitter systems, most drugs ultimately cause an acute increase in synaptic dopamine in the nucleus accumbens and the mesolimbic dopaminergic system (<xref ref-type="bibr" rid="bibr25-0269881111431750">Koob and Bloom, 1988</xref>; <xref ref-type="bibr" rid="bibr41-0269881111431750">Nestler, 2005</xref>; <xref ref-type="bibr" rid="bibr44-0269881111431750">Pierce and Kumaresan, 2006</xref>), as demonstrated by microdialysis studies in rats (<xref ref-type="bibr" rid="bibr14-0269881111431750">Di Chiara and Imperato, 1988</xref>) and positron emission tomography (PET) studies in humans (<xref ref-type="bibr" rid="bibr58-0269881111431750">Volkow et al., 1999</xref>, <xref ref-type="bibr" rid="bibr59-0269881111431750">2003</xref>, <xref ref-type="bibr" rid="bibr61-0269881111431750">2004</xref>, <xref ref-type="bibr" rid="bibr62-0269881111431750">2007</xref>, <xref ref-type="bibr" rid="bibr60-0269881111431750">2009</xref>). Several important observations have suggested that dopamine D<sub>3</sub> receptors may play a significant role in the effects of drugs of abuse and the pathophysiology of drug addiction (<xref ref-type="bibr" rid="bibr19-0269881111431750">Heidbreder et al., 2005</xref>; <xref ref-type="bibr" rid="bibr30-0269881111431750">Le Foll et al., 2005</xref>). First, dopamine D<sub>3</sub> receptors are located primarily in mesolimbic regions such as nucleus accumbens and ventral striatum (<xref ref-type="bibr" rid="bibr18-0269881111431750">Gurevich and Joyce, 1999</xref>; <xref ref-type="bibr" rid="bibr20-0269881111431750">Herroelen et al., 1994</xref>; <xref ref-type="bibr" rid="bibr29-0269881111431750">Landwehrmeyer et al., 1993</xref>; <xref ref-type="bibr" rid="bibr40-0269881111431750">Murray et al., 1994</xref>; <xref ref-type="bibr" rid="bibr48-0269881111431750">Seeman et al., 2006</xref>). Second, studies in animal models have demonstrated that dopamine D<sub>3</sub> receptor activation may be involved in the reinforcing effects and self-administration of cocaine (<xref ref-type="bibr" rid="bibr10-0269881111431750">Caine and Koob, 1993</xref>). Third, long-term drug exposure appears to cause upregulation of dopamine D<sub>3</sub> receptors as demonstrated in postmortem studies of cocaine overdose fatalities (<xref ref-type="bibr" rid="bibr52-0269881111431750">Staley and Mash, 1996</xref>; <xref ref-type="bibr" rid="bibr49-0269881111431750">Segal et al., 1997</xref>). Accordingly, it has been suggested that dopamine D<sub>3</sub> antagonism may be an effective strategy in the pharmacotherapy of addiction (<xref ref-type="bibr" rid="bibr19-0269881111431750">Heidbreder et al., 2005</xref>; <xref ref-type="bibr" rid="bibr23-0269881111431750">Joyce and Millan, 2005</xref>; <xref ref-type="bibr" rid="bibr31-0269881111431750">Levant, 1997</xref>).</p>
<p>GSK598809 is a novel, potent and selective dopamine D<sub>3</sub> receptor antagonist (<xref ref-type="bibr" rid="bibr47-0269881111431750">Searle et al., 2010</xref>), which is being developed as a novel treatment for substance dependence disorders. Functional assays showed that GSK598809 has greater than 100-fold selectivity for dopamine D<sub>3</sub> receptors over dopamine D<sub>2</sub>, histamine H<sub>1</sub>, muscarinic M<sub>1</sub>, M<sub>2</sub>, M<sub>3</sub>, M<sub>4</sub>, serotonin 5-HT<sub>1A</sub>, 5-HT<sub>1B</sub> and 5-HT<sub>1D</sub> receptors (data on file). Conditioned place preference (CPP) experiments in animal models indicated that GSK598809 significantly reduced nicotine- and cocaine-seeking behaviour in a dose-dependent manner (data on file). In addition, GSK598809 significantly prevented relapse to nicotine-seeking behaviour, although no effect was observed on reducing alcohol consumption in rats (data on file).</p>
<p>The present study was performed to evaluate the pharmacokinetics and central nervous system (CNS) effects of single oral doses of GSK598809 in healthy volunteers. Special emphasis was given to evaluating possible interactions with alcohol, because the target population of patients will have alcohol dependence as primary disorder, or may abuse alcohol as comorbidity next to another substance abuse disorder. Pharmacokinetic interactions between alcohol and GSK598809 are theoretically possible, because a metabolite of GSK598809 shows <italic>in vitro</italic> to have a potential for inhibiting CYP2E1, which is one of the main enzymes involved in alcohol metabolism (<xref ref-type="bibr" rid="bibr32-0269881111431750">Lieber, 1997</xref>). Also, pharmacodynamic interactions are theoretically possible as both compounds are centrally active and influence the dopamine system. However, apart from these theoretical possibilities, there are no reasons to assume <italic>a priori</italic> that any specific pharmacodynamic interaction will occur between GSK598809 and alcohol. Currently, no validated human pharmacodynamic markers for dopamine D<sub>3</sub> receptor antagonism are available. For exploratory purposes, a battery of quantitative CNS tests, sensitive to various compounds, including alcohol (<xref ref-type="bibr" rid="bibr66-0269881111431750">Zoethout et al., 2009</xref>) and antipsychotic drugs (dopamine D<sub>2</sub> receptor antagonists) (<xref ref-type="bibr" rid="bibr13-0269881111431750">de Visser et al., 2001</xref>), was used to evaluate pharmacodynamic effects. An oral dose of 175 mg GSK598809 was chosen because positron emission tomography using [<sup>11</sup>C]-(+)-PHNO in healthy volunteers has demonstrated that this dose can induce high occupancy (near 100%) of dopamine D<sub>3</sub> receptors in the substantia nigra (<xref ref-type="bibr" rid="bibr47-0269881111431750">Searle et al., 2010</xref>). Also, previous studies in healthy volunteers demonstrated that this dose is generally well tolerated (data on file).</p>
</sec>
<sec id="section2-0269881111431750" sec-type="methods">
<title>Methods</title>
<sec id="section3-0269881111431750">
<title>Study design</title>
<p>Twenty healthy volunteers, between 18 and 65 years of age and with a body mass index (BMI) between 18 and 30 kg/m<sup>2</sup>, were planned to participate in a blinded, randomized, placebo- controlled, double-dummy, four-period cross-over study. The study was approved by the medical ethics review board of the Leiden University Medical Center and registered at the NIH database of clinical trials (ClinicalTrials.gov identifier NCT00887367 and GSK ID number 106591). Prior to medical screening, all volunteers gave written informed consent. All volunteers underwent training sessions for the pharmacodynamic tests in order to minimize possible learning effects.</p>
<p>Volunteers were assigned to a randomized treatment sequence (see <xref ref-type="fig" rid="fig1-0269881111431750">Figure 1</xref>), consisting of one period of oral administration of 175 mg of GSK598809 combined with intravenous alcohol infusion (alcohol clamping, see below for further details), one period of oral administration of 175 mg of GSK598809 combined with intravenous placebo infusion, one period of oral placebo administration combined with intravenous alcohol infusion, and one period with oral placebo administration combined with intravenous placebo infusion. This study design enables analysis of the following comparisons (see <xref ref-type="fig" rid="fig1-0269881111431750">Figure 1</xref>):</p>
<list id="list1-0269881111431750" list-type="bullet">
<list-item><p>Administration of 175 mg GSK598809 (<italic>n</italic> = 20) versus placebo (<italic>n</italic> = 20).</p></list-item>
<list-item><p>Intravenous alcohol infusion (<italic>n</italic> = 20) versus placebo (<italic>n</italic> = 20).</p></list-item>
<list-item><p>Co-administration of 175 mg GSK598809 and intravenous alcohol infusion (<italic>n</italic> = 20) versus placebo (<italic>n</italic> = 20).</p></list-item>
<list-item><p>Co-administration of 175 mg GSK598809 and intravenous alcohol infusion (<italic>n</italic> = 20) versus intravenous alcohol infusion alone (<italic>n</italic> = 20).</p></list-item></list>
<fig id="fig1-0269881111431750" position="float">
<label>Figure 1.</label>
<caption>
<p>Study design.</p>
</caption>
<graphic xlink:href="10.1177_0269881111431750-fig1.tif"/>
</fig>
<p>GSK598809 or matching placebo was administered orally 30 minutes after the start of the ethanol (or placebo) infusion. The alcohol (or placebo) infusion continued for 5 hours in total to cover the main part of the plasma concentration curve of GSK598809. Each study period consisted of 5 study days. The randomized treatment was administered in the morning of the first study day, followed by pharmacokinetic and pharmacodynamic measurements at regular time points. All periods were separated by a wash-out time of at least 5 days.</p>
<p>Occasional (non-daily) smokers were eligible to participate in the study. Subjects were excluded from participation if they smoked on a daily basis. Also, subjects were excluded if they had an average alcohol daily intake of greater than 2 units (in case of females) or 3 units (in case of males) or an average weekly alcohol intake of greater than 14 units (in case of females) or 21 units (in case of males). One unit is equivalent to a half-pint (220 mL) of beer or one (25 mL) measure of spirits or one glass (125 mL) of wine. Subjects were instructed to abstain from smoking and alcoholic drinks on the day preceding all study periods and all subsequent study days. In addition, use of illicit drugs was not permitted. In all study periods, breath alcohol measurements were performed to ascertain non-use of alcohol. Also, urine drug screening for cocaine, amphetamines, opiates (morphine), benzodiazepines, barbiturates and THC (Innovacon, Inc., San Diego, California, USA) was performed to ascertain non-use of illicit drugs.</p>
</sec>
<sec id="section4-0269881111431750">
<title>Alcohol clamping</title>
<p>The method for attaining constant alcohol levels has been described in detail elsewhere (<xref ref-type="bibr" rid="bibr67-0269881111431750">Zoethout et al., 2008</xref>, <xref ref-type="bibr" rid="bibr66-0269881111431750">2009</xref>). In brief, alcohol (ethanol 10% w/v solution in 5% glucose) was infused intravenously over a period of 5 hours, guided by breath alcohol measurements to maintain a pseudo-steady state alcohol serum level of 0.6 g/L. This target level was chosen because this level produces significant CNS effects without causing too many inadvertent effects and is considered safe, since it is only just above the legal driving limit in the Netherlands (i.e. 0.5 g/L). Alcohol infusion started 30 minutes prior to administration of GSK598809. The infusion rate for the first 10 minutes was determined using demographic data of the volunteer (weight, height, age and gender). Infusion rates were subsequently adjusted, guided by breath alcohol measurements at baseline and at every five minutes for the first 30 minutes after the start of the infusion, every 10 minutes for the next 30 minutes and then every half hour until the end, using two calibrated Alco-Sensor IV Intoximeters (Honac, Apeldoorn, the Netherlands), which were alternated to avoid fatigue of the sensors. To prevent local pain at the beginning of the alcohol infusion, an additional diluting glucose 5% infusion at 100 mL/h was given to all participants during the first 10 minutes after the start of the alcohol infusion over the same infusion line. Alcohol clamping was performed in a randomized, double-blind, placebo-controlled fashion by an infusion assistant, who was not a member of the study team. A sham procedure, consisting of saline infusion in a manner similar to the alcohol infusion, including repeated breath alcohol measurements and subsequent infusion rate adjustments, was used to maintain blinding of the subject and the rest of the team. The mock infusion rate adjustments were provided by the clamping program.</p>
</sec>
<sec id="section5-0269881111431750">
<title>Safety monitoring</title>
<p>Evaluation of adverse events, 12-lead electrocardiograms (ECG), blood pressure, heart rate, alcohol breath test, urinalysis and blood sampling for haematology and chemistry was performed at regular time points after each dose administration. Automated oscillometric blood pressures were measured using a Nihon-Kohden BSM-1101K monitor or a Colin Pressmate BP 8800. ECGs were obtained with Cardiofax V equipped with ECAPS12 analysis program (Nihon-Kohden, Tokyo, Japan). In addition, telemetry monitoring was started at the beginning of alcohol infusion and was continued for 6 hours. Volunteers were evaluated for akathisia and extrapyramidal symptoms, using the Barnes Akathisia Rating Scale (<xref ref-type="bibr" rid="bibr3-0269881111431750">Barnes, 1989</xref>), Simpson–Angus Scale (<xref ref-type="bibr" rid="bibr50-0269881111431750">Simpson and Angus, 1970</xref>) and Abnormal Involuntary Movement Scale (<xref ref-type="bibr" rid="bibr39-0269881111431750">Munetz and Benjamin, 1988</xref>).</p>
</sec>
<sec id="section6-0269881111431750">
<title>Pharmacokinetics</title>
<p>Venous blood samples for GSK598809 concentration analysis were collected prior to dose administration and at 15 and 30 minutes and 1, 2, 3, 4, 6, 8, 10, 12, 24, 48 and 72 hours after dose administration. Concentration of GSK598809 in plasma samples was determined using protein precipitation followed by HPLC/MS analysis with a lower limit of quantification (LLQ) of 0.5 ng/mL. Pharmacokinetic parameters of GSK598809 include the maximum observed plasma concentration (<italic>C</italic><sub>max</sub>), time to reach maximum plasma concentration (<italic>t</italic><sub>max</sub>), area under the plasma concentration–time curve extrapolated to infinity (AUC<sub>∞</sub>) and terminal phase half-life (<italic>t</italic><sub>½</sub>).</p>
<p>Venous blood samples for pharmacokinetic analysis of serum alcohol were taken prior to start of infusion and at 15, 30, 45, 60, 90, 150, 210, 270 and 390 minutes after start of alcohol infusion. Serum alcohol levels were measured with an enzymatic assay (Roche Diagnostics, Mannheim, Germany) using a Hitachi 911 (Boehringer Mannheim, Mannheim, Germany). In this enzymatic assay, alcohol and nicotinamide adenine dinucleotide (NAD<sup>+</sup>) are converted to acetaldehyde and NADH by alcohol dehydrogenase (ADH). The NADH formed during the reaction, measured photometrically as a rate of change in absorbance, is directly proportional to the alcohol concentration.</p>
</sec>
<sec id="section7-0269881111431750">
<title>Pharmacodynamic testing</title>
<p>All pharmacodynamic measurements were performed as described previously (<xref ref-type="bibr" rid="bibr12-0269881111431750">de Haas et al., 2009</xref>; <xref ref-type="bibr" rid="bibr33-0269881111431750">Liem-Moolenaar et al., 2010a</xref>). Volunteers were tested individually in a quiet room with ambient illumination. Quantitative tests, sensitive to the effects of alcohol (<xref ref-type="bibr" rid="bibr66-0269881111431750">Zoethout et al., 2009</xref>) and single oral doses of antipsychotic drugs (dopamine D<sub>2</sub> receptor antagonists) (<xref ref-type="bibr" rid="bibr13-0269881111431750">de Visser et al., 2001</xref>) such as haloperidol (<xref ref-type="bibr" rid="bibr33-0269881111431750">Liem-Moolenaar et al., 2010a</xref>, <xref ref-type="bibr" rid="bibr35-0269881111431750">2010b</xref>) and risperidone (<xref ref-type="bibr" rid="bibr34-0269881111431750">Liem-Moolenaar et al., 2011</xref>) in healthy volunteers, included measurements of smooth pursuit and saccadic eye movements, adaptive tracking, body sway, visual analogue scales (VAS), the visual verbal learning test (VVLT) and serum prolactin levels. Previous studies using the alcohol clamping paradigm and this pharmacodynamic test battery (<xref ref-type="bibr" rid="bibr66-0269881111431750">Zoethout et al., 2009</xref>) demonstrated that smooth pursuit eye movements and body sway were the most sensitive pharmacodynamic parameters for the effects of alcohol. In order to obtain accurate time profiles of the effects of alcohol and GSK598809, smooth pursuit eye movements and body sway were recorded at a high frequency. The other pharmacodynamic tests were performed less frequently due to limitations in time and logistics.</p>
</sec>
<sec id="section8-0269881111431750">
<title>Analysis of eye movements</title>
<p>To evaluate oculomotor performance and sedation, smooth pursuit and saccadic eye movements were recorded as described previously (<xref ref-type="bibr" rid="bibr2-0269881111431750">Baloh et al., 1975</xref>; <xref ref-type="bibr" rid="bibr5-0269881111431750">Bittencourt et al., 1983</xref>; <xref ref-type="bibr" rid="bibr56-0269881111431750">van Steveninck et al., 1991</xref>, <xref ref-type="bibr" rid="bibr57-0269881111431750">1999</xref>), using a microcomputer-based system for data recording and analysis (Cambridge Electronic Design Ltd., Cambridge, UK), Nihon-Kohden equipment for stimulus display, signal collection and amplification (Nihon-Kohden, Tokyo, Japan), and disposable surface electrodes (Medicotest N-OO-S, Olstykke, Denmark). For smooth pursuit eye movements, a target light source moves sinusoidally over 20<sup>○</sup> eyeball rotation at frequencies ranging from 0.3 to 1.1 Hz. The time in which the eyes were in smooth pursuit was calculated for each frequency and expressed as the percentage of stimulus duration. The average percentage of smooth pursuit for all frequencies was used as a parameter. Smooth pursuit eye movements were recorded prior to dose administration and at 10, 20, 30, 60, 90, 120, 150, 180, 210, 240, 270, 300, 330, 360, 390, 420 and 450 minutes after dose administration. For saccadic eye movements, the target light source jumps from side to side. Peak velocity (degrees per second), reaction time and inaccuracy (%) was calculated of all artefact-free saccades. Saccadic eye movements were recorded prior to dose administration and at 30, 90, 150, 210, 270, 330, 390 and 450 minutes after dose administration.</p>
</sec>
<sec id="section9-0269881111431750">
<title>Adaptive tracking</title>
<p>To evaluate visuo-motor coordination, the adaptive tracking task was performed as described previously (<xref ref-type="bibr" rid="bibr7-0269881111431750">Borland and Nicholson, 1984</xref>; <xref ref-type="bibr" rid="bibr56-0269881111431750">van Steveninck et al., 1991</xref>, <xref ref-type="bibr" rid="bibr55-0269881111431750">1993</xref>, <xref ref-type="bibr" rid="bibr57-0269881111431750">1999</xref>; <xref ref-type="bibr" rid="bibr16-0269881111431750">Gijsman et al., 1998</xref>), using customized equipment and software developed by K.W. Hobbs (Hertfordshire, UK). Adaptive tracking is a pursuit tracking task in which a circle moves randomly over a computer screen and the volunteer must try to keep a dot inside the moving circle using a joystick. If this effort is successful, the speed of the moving circle is increased and if the effort is unsuccessful, the speed is reduced. The adaptive tracking task was performed prior to dose administration and at 30, 90, 150, 210, 270, 330, 390 and 450 minutes after dose administration and performance was scored over a fixed period of 3 minutes. Average performance and standard deviation of scores were used for analysis.</p>
</sec>
<sec id="section10-0269881111431750">
<title>Body sway</title>
<p>Postural stability in the sagittal plane was measured with an apparatus similar to the Wright ataxiameter (<xref ref-type="bibr" rid="bibr64-0269881111431750">Wright, 1971</xref>), using a string attached to the waist of the volunteer. Measurements were performed prior to dose administration and at 10, 20, 30, 60, 90, 120, 150, 180, 210, 240, 270, 300, 330, 360, 390, 420 and 450 minutes after dose administration. Movements over a period of 2 minutes, while standing still with eyes closed, were integrated and expressed as millimetres sway.</p>
</sec>
<sec id="section11-0269881111431750">
<title>Visual analogue scales</title>
<p>Subjective effects were quantified prior to dose administration and at 30, 90, 150, 210, 270, 330, 390 and 450 minutes after dose administration using a Dutch translation of the VAS, originally described by <xref ref-type="bibr" rid="bibr42-0269881111431750">Norris (1971)</xref>, to derive three composite factors corresponding to alertness, mood (contentedness) and calmness, as described by <xref ref-type="bibr" rid="bibr6-0269881111431750">Bond and Lader (1974)</xref>. In addition, a VAS was used to quantify the subjective effects of alcohol.</p>
</sec>
<sec id="section12-0269881111431750">
<title>Visual verbal learning test</title>
<p>The VVLT (<xref ref-type="bibr" rid="bibr46-0269881111431750">Schmitt et al., 2000</xref>) is an adapted version of the auditory verbal learning test (<xref ref-type="bibr" rid="bibr45-0269881111431750">Rey, 1964</xref>) and was performed 150 minutes after dose administration. Three trials of 30 words are presented on a computer screen in the same sequence. The volunteer is requested to reproduce as many words as possible at the ending of each trial (immediate recall) and after 30 minutes (delayed recall). The number of correctly reproduced words is analyzed for each trial. Also, a recognition test is performed, consisting of 15 previously presented words and 15 new words, in which the volunteer has to indicate recognition of the word (delayed recognition) as quickly as possible. Response time and the number of correctly recognized words are analyzed.</p>
</sec>
<sec id="section13-0269881111431750">
<title>Serum prolactin levels</title>
<p>Blood samples for measurement of prolactin levels were collected at baseline and at 60, 90, 120, 210, 390, 720 and 1320 minutes after study drug administration and serum was separated by centrifugation (2000 g at 4<sup>○</sup>C for 10 minutes). Prolactin levels were determined using an electrochemiluminescence immunoassay (ECLIA) on a Modular Analytics E170 (Elecsys module) immunoassay analyzer.</p>
</sec>
<sec id="section14-0269881111431750">
<title>Statistical analysis</title>
<p>Analysis of variance models were performed on the pharmacokinetic parameters, including the factors treatment and period as fixed effects and subject as random effect. AUC and <italic>C</italic><sub>max</sub> pharmacokinetic parameters were log-transformed prior to analysis. Comparisons were expressed as ratios of the pharmacokinetic parameters after GSK598809 combined with ethanol relative to those after alcohol alone or relative to those after GSK598809 alone.</p>
<p>Pharmacodynamic data were compared using a mixed model analysis of variance with treatment, gender, period, time, and treatment by time as fixed factors, and with subject, subject by treatment and subject by time as random factors. VVLT data were compared using a mixed model analysis of variance with treatment, gender and period as fixed factors, and with subject as random factor. The parameters body sway, prolactin, saccadic eye movements and the delayed word variables were log-transformed prior to analysis to correct for the expected log-normal distribution of the data. The following contrasts were calculated (see <xref ref-type="fig" rid="fig1-0269881111431750">Figure 1</xref>): alcohol versus placebo, GSK598809 versus placebo, co-administration of GSK598809 and alcohol versus placebo, co-administration of GSK598809 and alcohol versus alcohol alone.</p>
<p>Supra-additive effects (defined as effects, resulting from co-administration of two independent agents, being greater than the sum of effects of each individual agent) were evaluated by analyzing the contrast of the effects of co-administration of GSK598809 and alcohol with subtraction of the effects of GSK598809 alone versus the effects of alcohol alone with subtraction of the effects of placebo:</p>
<p>
<disp-formula id="disp-formula1-0269881111431750">
<mml:math display="block" id="math1-0269881111431750">
<mml:mtable columnalign="left">
<mml:mtr>
<mml:mtd>
<mml:mrow>
<mml:mo>[</mml:mo>
<mml:mrow>
<mml:mrow>
<mml:mo>(</mml:mo>
<mml:mtable columnalign="left">
<mml:mtr>
<mml:mtd>
<mml:mtext>effects of</mml:mtext>
</mml:mtd>
</mml:mtr>
<mml:mtr>
<mml:mtd>
<mml:mtext>GSK598809 and alcohol</mml:mtext>
</mml:mtd>
</mml:mtr>
</mml:mtable>
<mml:mo>)</mml:mo>
</mml:mrow>
<mml:mo>−</mml:mo>
<mml:mrow>
<mml:mo>(</mml:mo>
<mml:mtable columnalign="left">
<mml:mtr>
<mml:mtd>
<mml:mtext>effects of</mml:mtext>
</mml:mtd>
</mml:mtr>
<mml:mtr>
<mml:mtd>
<mml:mtext>GSK598809 alone</mml:mtext>
</mml:mtd>
</mml:mtr>
</mml:mtable>
<mml:mo>)</mml:mo>
</mml:mrow>
</mml:mrow>
<mml:mo>]</mml:mo>
</mml:mrow>
</mml:mtd>
</mml:mtr>
<mml:mtr>
<mml:mtd>
<mml:mtext>versus</mml:mtext>
<mml:mrow>
<mml:mo>[</mml:mo>
<mml:mrow>
<mml:mrow>
<mml:mo>(</mml:mo>
<mml:mtable columnalign="left">
<mml:mtr>
<mml:mtd>
<mml:mtext>effects of</mml:mtext>
</mml:mtd>
</mml:mtr>
<mml:mtr>
<mml:mtd>
<mml:mtext>alcohol alone</mml:mtext>
</mml:mtd>
</mml:mtr>
</mml:mtable>
<mml:mo>)</mml:mo>
</mml:mrow>
<mml:mo>−</mml:mo>
<mml:mrow>
<mml:mo>(</mml:mo>
<mml:mtable columnalign="left">
<mml:mtr>
<mml:mtd>
<mml:mtext>effects of</mml:mtext>
</mml:mtd>
</mml:mtr>
<mml:mtr>
<mml:mtd>
<mml:mtext>placebo</mml:mtext>
</mml:mtd>
</mml:mtr>
</mml:mtable>
<mml:mo>)</mml:mo>
</mml:mrow>
</mml:mrow>
<mml:mo>]</mml:mo>
</mml:mrow>
</mml:mtd>
</mml:mtr>
</mml:mtable>
</mml:math>
<graphic alternate-form-of="disp-formula1-0269881111431750" xlink:href="10.1177_0269881111431750-eq1.tif"/>
</disp-formula>
</p>
<p>After identifying gender effects on prolactin levels, analysis of prolactin data was repeated using a mixed model analysis of variance with treatment, gender, period, time, treatment by gender, treatment by time, gender by time and treatment by gender by time as fixed factors, and with subject, subject by treatment and subject by time as random factors. Contrasts were calculated in original measurement unit with 95% confidence intervals and the associated <italic>p</italic>-value, except for the log-transformed parameters, which were calculated as a percentage relative to placebo or alcohol. All calculations were performed using SAS for Windows version 9.1.3 (SAS Institute Inc., Cary, North Carolina, USA).</p>
</sec></sec>
<sec id="section15-0269881111431750" sec-type="results">
<title>Results</title>
<sec id="section16-0269881111431750">
<title>Subjects</title>
<p>Twenty volunteers (10 males and 10 females) were included in the study. Volunteers had a mean age of 32.8 years (range 18–55), weight of 73.5 kg (range 54–108) and BMI of 23.6 kg/m<sup>2</sup> (range 18.5–29.8). One female volunteer tested positive for benzodiazepines on the drug screen in study period 2 and thereby violated the exclusion criteria. She was subsequently withdrawn from the study and not replaced. This volunteer was administered alcohol infusion and placebo capsules in the first study period.</p>
</sec>
<sec id="section17-0269881111431750">
<title>Clinical observations</title>
<p>All adverse events were transient and mild or moderate in severity and no serious adverse events occurred during the study. Overall, the most frequent adverse effect were headache, somnolence, feeling drunk, dizziness, fatigue, pain at infusion site, nausea and vomiting (see <xref ref-type="table" rid="table1-0269881111431750">Table 1</xref>). Somnolence and fatigue were reported more frequently after GSK598809 administration combined with alcohol (<italic>n</italic> = 18), compared with alcohol alone (<italic>n</italic> = 8), GSK598809 alone (<italic>n</italic> = 4) or placebo (<italic>n</italic> = 4). There were no consistent and clinically relevant changes on the Barnes Akathisia Rating Scale, Simpson–Angus Scale and Abnormal Involuntary Movement Scale. Mild short-lasting akathisia was reported spontaneously once after administration of GSK598809 combined with alcohol and once after GSK598809 alone, but these events were not verified objectively by the Barnes Akathisia Rating Scale, when this was performed as scheduled. There were no consistent and clinically relevant changes in vital signs, blood chemistry and haematology or any of the ECG intervals.</p>
<table-wrap id="table1-0269881111431750" position="float">
<label>Table 1.</label>
<caption>
<p>Summary of common adverse events, reported by two subjects or more. Incidence is based on the number of subjects, not the number of events</p>
</caption>
<graphic alternate-form-of="table1-0269881111431750" xlink:href="10.1177_0269881111431750-table1.tif"/>
<table>
<colgroup>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
</colgroup>
<thead>
<tr>
<th align="left">Adverse event</th>
<th align="left">Placebo <italic>n</italic> = 19</th>
<th align="left">Alcohol <italic>n</italic> = 20</th>
<th align="left">GSK598809 <italic>n</italic> = 19</th>
<th align="left">GSK598809 + Alcohol <italic>n</italic> = 19</th>
</tr>
</thead>
<tbody>
<tr>
<td>Headache</td>
<td>6 (32%)</td>
<td>9 (45%)</td>
<td>5 (26%)</td>
<td>7 (37%)</td>
</tr>
<tr>
<td>Somnolence</td>
<td>1 (5%)</td>
<td>4 (20%)</td>
<td>3 (16%)</td>
<td>11 (58%)</td>
</tr>
<tr>
<td>Dizziness</td>
<td>1 (5%)</td>
<td>6 (30%)</td>
<td>6 (32%)</td>
<td>5 (26%)</td>
</tr>
<tr>
<td>Akathisia</td>
<td>0</td>
<td>0</td>
<td>1 (5%)</td>
<td>1 (5%)</td>
</tr>
<tr>
<td>Feeling drunk</td>
<td>0</td>
<td>7 (35%)</td>
<td>0</td>
<td>6 (32%)</td>
</tr>
<tr>
<td>Fatigue</td>
<td>3 (16%)</td>
<td>4 (20%)</td>
<td>1 (5%)</td>
<td>7 (37%)</td>
</tr>
<tr>
<td>Infusion site pain</td>
<td>0</td>
<td>3 (15%)</td>
<td>0</td>
<td>2 (11%)</td>
</tr>
<tr>
<td>Catheter site related reaction</td>
<td>0</td>
<td>1 (5%)</td>
<td>1 (5%)</td>
<td>0</td>
</tr>
<tr>
<td>Nausea</td>
<td>0</td>
<td>1 (5%)</td>
<td>3 (16%)</td>
<td>3 (16%)</td>
</tr>
<tr>
<td>Vomiting</td>
<td>0</td>
<td>1 (5%)</td>
<td>4 (21%)</td>
<td>0</td>
</tr>
<tr>
<td>Dry mouth</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>2 (11%)</td>
</tr>
<tr>
<td>Upper respiratory tract infection</td>
<td>0</td>
<td>2 (10%)</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Dysmenorrhoea</td>
<td>1 (5%)</td>
<td>0</td>
<td>0</td>
<td>1 (5%)</td>
</tr>
<tr>
<td>Oropharyngeal discomfort</td>
<td>1 (5%)</td>
<td>0</td>
<td>0</td>
<td>1 (5%)</td>
</tr>
<tr>
<td>Skin reaction</td>
<td>1 (5%)</td>
<td>1 (5%)</td>
<td>0</td>
<td>0</td>
</tr>
</tbody>
</table>
</table-wrap>
</sec>
<sec id="section18-0269881111431750">
<title>Pharmacokinetics of alcohol</title>
<p>Following intravenous infusion, serum alcohol concentration increased rapidly and remained constant at the target level all over the time of infusion, after which serum concentrations declined (see <xref ref-type="fig" rid="fig2-0269881111431750">Figure 2</xref>).</p>
<fig id="fig2-0269881111431750" position="float">
<label>Figure 2.</label>
<caption>
<p>Serum alcohol levels after intravenous alcohol infusion starting at <italic>t</italic> = −0.5 hours and continuing until <italic>t</italic> = 4.5 hours, in combination with oral administration (at <italic>t</italic> = 0 hours) of GSK598809 (open circles) or placebo (closed circles). Means are presented with standard deviations as error bars.</p>
</caption>
<graphic xlink:href="10.1177_0269881111431750-fig2.tif"/>
</fig>
</sec>
<sec id="section19-0269881111431750">
<title>Pharmacokinetics of GSK598809</title>
<p>Pharmacokinetic parameters are presented in <xref ref-type="table" rid="table2-0269881111431750">Table 2</xref>. Oral administration of GSK598809 resulted in peak levels after roughly 2–3 hours (see <xref ref-type="fig" rid="fig3-0269881111431750">Figure 3</xref>) with an apparent bi-exponential decline and a half-life of roughly 20 hours.</p>
<table-wrap id="table2-0269881111431750" position="float">
<label>Table 2.</label>
<caption>
<p>Pharmacokinetic parameters of GSK598809 with and without co-administration of alcohol. Data are presented as geometric means (with coefficient of variation), except <italic>t</italic><sub>max</sub> which is presented as median (with range).</p>
</caption>
<graphic alternate-form-of="table2-0269881111431750" xlink:href="10.1177_0269881111431750-table2.tif"/><table>
<colgroup>
<col align="left"/>
<col align="left"/>
<col align="left"/>
</colgroup>
<thead>
<tr>
<th align="left">Parameter</th>
<th align="left">GSK598809</th>
<th align="left">GSK598809 + alcohol</th>
</tr>
</thead>
<tbody>
<tr>
<td><italic>C</italic><sub>max</sub> (ng/mL)</td>
<td>1320 (39)</td>
<td>1190 (39)</td>
</tr>
<tr>
<td><italic>t</italic><sub>max</sub> (h)</td>
<td>2.07 (2.0-6.05)</td>
<td>3.03 (2.00-7.87)</td>
</tr>
<tr>
<td>AUC<sub>0-t</sub> (ng.h/mL)</td>
<td>14000 (28)</td>
<td>15700 (27)</td>
</tr>
<tr>
<td>AUC<sub>∞</sub> (ng.h/mL)</td>
<td>14000 (32)</td>
<td>16600 (23)</td>
</tr>
<tr>
<td>Terminal half life (h)</td>
<td>19.3 (33)</td>
<td>21.6 (27)</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn1-0269881111431750">
<p><italic>n</italic> = 19 for all calculated values, except <italic>t</italic><sub>½</sub> and AUC<sub>∞</sub> of GSK598809 alone (<italic>n</italic> = 11) and combined with alcohol (<italic>n</italic> = 15), because these parameters could not be calculated reliably in 8 subjects and 4 subjects, respectively</p>
</fn>
</table-wrap-foot>
</table-wrap>
<fig id="fig3-0269881111431750" position="float">
<label>Figure 3.</label>
<caption>
<p>Plasma concentrations of GSK598809 after oral administration (at <italic>t</italic> = 0 hours), in combination with intravenous alcohol infusion (open circles) or placebo infusion (closed circles) starting at <italic>t</italic> = −0.5 hours and continuing until <italic>t</italic> = 4.5 hours. Means are presented with standard deviations as error bars.</p>
</caption>
<graphic xlink:href="10.1177_0269881111431750-fig3.tif"/>
</fig>
</sec>
<sec id="section20-0269881111431750">
<title>Pharmacokinetics of GSK598809 combined with alcohol</title>
<p>No relevant effect of GSK598809 on ethanol pharmacokinetic parameters was observed. Regarding the effects of alcohol on GSK598809 pharmacokinetic parameters, an average 15% increase in AUC<sub>∞</sub> of GSK598809 (ratio of LS geometric means 1.15; 90% confidence interval 1.02–1.30) and an average 9% decrease in <italic>C</italic><sub>max</sub> of GSK598809 (ratio of LS geometric means 0.91; 90% confidence interval 0.83–1.00) was observed after administration of GSK598809 combined with alcohol compared with GSK598809 alone. Other parameters were roughly similar compared with GSK598809 alone (see <xref ref-type="table" rid="table2-0269881111431750">Table 2</xref>).</p>
</sec>
<sec id="section21-0269881111431750">
<title>Pharmacodynamics of alcohol</title>
<p>Following alcohol infusion, a statistically significant decrease in adaptive tracking and smooth pursuit eye movements and increase in body sway were observed compared with placebo, but there were no effects on saccadic peak velocity, inaccuracy or reaction time (see <xref ref-type="table" rid="table3-0269881111431750">Table 3</xref> and <xref ref-type="fig" rid="fig4-0269881111431750">Figures 4</xref>–<xref ref-type="fig" rid="fig7-0269881111431750">7</xref>). Clear increases in the feeling of being drunk were noted. In addition, there was some decrease in alertness on the VAS Bond and Lader scales, compared with placebo (see <xref ref-type="table" rid="table4-0269881111431750">Table 4</xref> and <xref ref-type="fig" rid="fig8-0269881111431750">Figure 8</xref>). Alcohol did not demonstrate any clear effect on VVLT performance (see <xref ref-type="table" rid="table5-0269881111431750">Table 5</xref>).</p>
<table-wrap id="table3-0269881111431750" position="float">
<label>Table 3.</label>
<caption>
<p>Neurophysiological effects of administration of alcohol alone, GSK598809 alone and co-administration of GSK598009 and alcohol. Treatment differences in least square means are shown with statistically significant results indicated in bold</p>
</caption>
<graphic alternate-form-of="table3-0269881111431750" xlink:href="10.1177_0269881111431750-table3.tif"/>
<table>
<colgroup>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
</colgroup>
<thead>
<tr>
<th align="left">Parameter</th>
<th align="left">Alcohol compared with placebo</th>
<th align="left">GSK598809 compared with placebo</th>
<th align="left">GSK598809 + alcohol compared with placebo</th>
<th align="left">GSK598809 + alcohol compared with alcohol alone</th>
<th align="left">Supra-additive effects</th>
</tr>
</thead>
<tbody>
<tr>
<td colspan="6">Prolactin (ng/mL)</td>
</tr>
<tr>
<td> Contrast<break/> 95% CI<break/> <italic>p</italic>-value</td>
<td>5.33%<break/>−6.17/18.25%<break/>0.3711</td>
<td><bold>118.4%</bold><break/><bold>94.49/145.1%</bold><break/><bold>≤0.0001</bold></td>
<td><bold>113.1%</bold><break/><bold>89.74/139.3%</bold><break/><bold>≤0.0001</bold></td>
<td><bold>102.3%</bold><break/><bold>80.26/127.1%</bold><break/><bold>≤0.0001</bold></td>
<td>−7.35%<break/>−21.3/9.10%<break/>0.3525</td>
</tr>
<tr>
<td colspan="6">Saccadic peak velocity (deg/sec)</td>
</tr>
<tr>
<td> Contrast<break/>95% CI<break/> <italic>p</italic>-value</td>
<td>−2.53%<break/>−5.01/0.01%<break/>0.0505</td>
<td>−1.98%<break/>−4.45/0.57%<break/>0.1239</td>
<td><bold>−7.15%</bold><break/><bold>−9.51/−4.72%</bold><break/><bold>≤0.0001</bold></td>
<td><bold>−4.73%</bold><break/><bold>−7.18/−2.22%</bold><break/><bold>0.0005</bold></td>
<td>−2.81%<break/>−6.30/0.80%<break/>0.1229</td>
</tr>
<tr>
<td colspan="6">Saccadic inaccuracy (%)</td>
</tr>
<tr>
<td> Contrast<break/> 95% CI<break/> <italic>p</italic>-value</td>
<td>−0.23%<break/>−8.67/9.00%<break/>0.9592</td>
<td>3.96%<break/>−4.82/13.56%<break/>0.3805</td>
<td><bold>10.17%</bold><break/><bold>0.79/20.42%</bold><break/><bold>0.0334</bold></td>
<td><bold>10.42%</bold><break/><bold>0.97/20.75%</bold><break/><bold>0.0306</bold></td>
<td>6.21%<break/>−6.34/20.45%<break/>0.3405</td>
</tr>
<tr>
<td colspan="6">Saccadic reaction time<break/>(sec)</td>
</tr>
<tr>
<td> Contrast<break/> 95% CI<break/> <italic>p</italic>-value</td>
<td>2.51%<break/>−0.43/5.54%<break/>0.0937</td>
<td>2.09%<break/>−0.83/5.09%<break/>0.1584</td>
<td><bold>9.20%</bold><break/><bold>6.05/12.44%</bold><break/><bold>≤0.0001</bold></td>
<td><bold>6.53%</bold><break/><bold>3.43/9.72%</bold><break/><bold>≤0.0001</bold></td>
<td><bold>4.35%</bold><break/><bold>0.11/8.76%</bold><break/><bold>0.0443</bold></td>
</tr>
<tr>
<td colspan="6">Smooth pursuit (%)</td>
</tr>
<tr>
<td> Contrast<break/> 95% CI<break/> <italic>p</italic>-value</td>
<td><bold>−6.9</bold><break/><bold>−10.1/−3.7</bold><break/><bold>≤0.0001</bold></td>
<td>−0.9<break/>−4.1/2.3<break/>0.5930</td>
<td><bold>−6.1</bold><break/><bold>−9.3/−2.9</bold><break/><bold>0.0004</bold></td>
<td>0.8<break/>−2.4/4.0<break/>0.6210</td>
<td>1.7<break/>−2.9/6.2<break/>0.4674</td>
</tr>
<tr>
<td colspan="6">Adaptive tracking (%)</td>
</tr>
<tr>
<td> Contrast<break/> 95% CI<break/><italic> p</italic>-value</td>
<td><bold>−2.0</bold><break/><bold>−3.7/−0.3</bold><break/><bold>0.0207</bold></td>
<td><bold>−2.0</bold><break/><bold>−3.7/−0.3</bold><break/><bold>0.0227</bold></td>
<td><bold>−5.6</bold><break/><bold>−7.3/−3.9</bold><break/><bold>≤0.0001</bold></td>
<td><bold>−3.5</bold><break/><bold>−5.2/−1.8</bold><break/><bold>0.0001</bold></td>
<td>−1.5<break/>−3.9/0.9<break/>0.2099</td>
</tr>
<tr>
<td colspan="6">Body sway (mm)</td>
</tr>
<tr>
<td> Contrast<break/> 95% CI<break/> <italic>p</italic>-value</td>
<td><bold>31.83%</bold><break/><bold>9.96/58.06%</bold><break/><bold>0.0035</bold></td>
<td>4.80%<break/>−12.6/25.70%<break/>0.6066</td>
<td><bold>41.31%</bold><break/><bold>17.69/69.67%</bold><break/><bold>0.0004</bold></td>
<td>7.18%<break/>−10.7/28.67%<break/>0.4493</td>
<td>2.27%<break/>−21.0/32.33%<break/>0.8618</td>
</tr>
</tbody>
</table></table-wrap>
<fig id="fig4-0269881111431750" position="float">
<label>Figure 4.</label>
<caption>
<p>Time course of smooth pursuit eye movements following administration of GSK598809 capsules combined with alcohol infusion (open circles), GSK598809 capsules combined with placebo infusion (closed circles), placebo capsules combined with alcohol infusion (open triangles) and placebo capsules combined with placebo infusion (closed triangles). Least square means are presented with 95% confidence intervals as error bars.</p>
</caption>
<graphic xlink:href="10.1177_0269881111431750-fig4.tif"/>
</fig>
<fig id="fig5-0269881111431750" position="float">
<label>Figure 5.</label>
<caption>
<p>Time course of saccadic peak velocity following administration of GSK598809 capsules combined with alcohol infusion (open circles), GSK598809 capsules combined with placebo infusion (closed circles), placebo capsules combined with alcohol infusion (open triangles) and placebo capsules combined with placebo infusion (closed triangles). Least square means are presented with 95% confidence intervals as error bars.</p>
</caption>
<graphic xlink:href="10.1177_0269881111431750-fig5.tif"/>
</fig>
<fig id="fig6-0269881111431750" position="float">
<label>Figure 6.</label>
<caption>
<p>Time course of adaptive tracking performance following administration of GSK598809 capsules combined with alcohol infusion (open circles), GSK598809 capsules combined with placebo infusion (closed circles), placebo capsules combined with alcohol infusion (open triangles) and placebo capsules combined with placebo infusion (closed triangles). Least square means are presented with 95% confidence intervals as error bars.</p>
</caption>
<graphic xlink:href="10.1177_0269881111431750-fig6.tif"/>
</fig>
<fig id="fig7-0269881111431750" position="float">
<label>Figure 7.</label>
<caption>
<p>Time course of body sway following administration of GSK598809 capsules combined with alcohol infusion (open circles), GSK598809 capsules combined with placebo infusion (closed circles), placebo capsules combined with alcohol infusion (open triangles) and placebo capsules combined with placebo infusion (closed triangles). Least square means are presented with 95% confidence intervals as error bars.</p>
</caption>
<graphic xlink:href="10.1177_0269881111431750-fig7.tif"/>
</fig>
<table-wrap id="table4-0269881111431750" position="float">
<label>Table 4.</label>
<caption>
<p>VAS results after administration of alcohol alone, GSK598809 alone and co-administration of GSK598009 and alcohol. Treatment differences in least square means are shown with statistically significant results indicated in bold</p>
</caption>
<graphic alternate-form-of="table4-0269881111431750" xlink:href="10.1177_0269881111431750-table4.tif"/>
<table>
<colgroup>
<col align="left"/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
</colgroup>
<thead>
<tr>
<th align="left">Parameter</th>
<th align="left">Alcohol compared with placebo</th>
<th align="left">GSK598809 compared with placebo</th>
<th align="left">GSK598809 + alcohol compared with placebo</th>
<th align="left">GSK598809 + alcohol compared with alcohol alone</th>
<th align="left">Supra-additive effects</th>
</tr>
</thead>
<tbody>
<tr>
<td colspan="6">VAS alertness (mm)</td>
</tr>
<tr>
<td> Contrast<break/> 95% CI<break/> <italic>p</italic>-value</td>
<td><bold>−6.9</bold><break/><bold>−11.4/−2.4</bold><break/><bold>0.0031</bold></td>
<td>−3.3<break/>−7.9/1.2<break/>0.1428</td>
<td><bold>−8.4</bold><break/><bold>−12.9/−3.9</bold><break/><bold>0.0005</bold></td>
<td>−1.5<break/>−6.0/3.0<break/>0.5134</td>
<td>1.9<break/>−4.5/8.2<break/>0.5574</td>
</tr>
<tr>
<td colspan="6">VAS calmness (mm)</td>
</tr>
<tr>
<td> Contrast<break/> 95% CI<break/> <italic>p</italic>-value</td>
<td>−1.5<break/>−3.8/0.8<break/>0.1911</td>
<td>−0.3<break/>−2.6/2.0<break/>0.7964</td>
<td>−0.9<break/>−3.2/1.4<break/>0.4288</td>
<td>0.6<break/>−1.7/2.9<break/>0.6024</td>
<td>0.9<break/>−2.4/4.2<break/>0.5820</td>
</tr>
<tr>
<td colspan="6">VAS mood (mm)</td>
</tr>
<tr>
<td> Contrast<break/> 95% CI<break/> <italic>p</italic>-value</td>
<td>−2.0<break/>−5.0/0.9<break/>0.1761</td>
<td>−0.9<break/>−3.9/2.1<break/>0.5537</td>
<td>−0.9<break/>−3.9/2.1<break/>0.5415</td>
<td>1.1<break/>−1.9/4.1<break/>0.4542</td>
<td>2.0<break/>−2.2/6.2<break/>0.3442</td>
</tr>
<tr>
<td colspan="6">VAS alcohol effects (mm)</td>
</tr>
<tr>
<td> Contrast<break/> 95% CI<break/> <italic>p</italic>-value</td>
<td><bold>23.1</bold><break/><bold>13.4/32.8</bold><break/><bold>≤0.0001</bold></td>
<td>2.1<break/>−7.6/11.8<break/>0.6650</td>
<td><bold>24.6</bold><break/><bold>14.9/34.3</bold><break/><bold>≤0.0001</bold></td>
<td>1.5<break/>−8.2/11.2<break/>0.7588</td>
<td>−0.6<break/>−14.3/13.1<break/>0.9280</td>
</tr>
</tbody>
</table>
</table-wrap>
<fig id="fig8-0269881111431750" position="float">
<label>Figure 8.</label>
<caption>
<p>Time course of alertness (visual analogue scales of <xref ref-type="bibr" rid="bibr6-0269881111431750">Bond and Lader (1974)</xref>) following administration of GSK598809 capsules combined with alcohol infusion (open circles), GSK598809 capsules combined with placebo infusion (closed circles), placebo capsules combined with alcohol infusion (open triangles) and placebo capsules combined with placebo infusion (closed triangles). Least square means are presented with 95% confidence intervals as error bars.</p>
</caption>
<graphic xlink:href="10.1177_0269881111431750-fig8.tif"/>
</fig>
<table-wrap id="table5-0269881111431750" position="float">
<label>Table 5.</label>
<caption>
<p>VVLT results after administration of alcohol alone, GSK598809 alone and co-administration of GSK598009 and alcohol. Treatment differences in least square means are shown with statistically significant results indicated in bold</p>
</caption>
<graphic alternate-form-of="table5-0269881111431750" xlink:href="10.1177_0269881111431750-table5.tif"/>
<table>
<colgroup>
<col align="left"/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
</colgroup>
<thead>
<tr>
<th align="left">Parameter</th>
<th align="left">Alcohol compared with placebo</th>
<th align="left">GSK598809 compared with placebo</th>
<th align="left">GSK598809 + alcohol compared with placebo</th>
<th align="left">GSK598809 + alcohol compared with alcohol alone</th>
<th align="left">Supra-additive effects</th>
</tr>
</thead>
<tbody>
<tr>
<td colspan="6">Immediate recall 1<sup>st</sup> trial</td>
</tr>
<tr>
<td> Contrast<break/> 95% CI<break/> <italic>p</italic>-value</td>
<td>−0.3<break/>−1.6/1.1<break/>0.6812</td>
<td>0.3<break/>−1.1/1.7<break/>0.6725</td>
<td>−0.8<break/>−2.1/0.6<break/>0.2516</td>
<td>−0.5<break/>−1.8/0.8<break/>0.4554</td>
<td>−0.8<break/>−2.7/1.1<break/>0.4115</td>
</tr>
<tr>
<td colspan="6">Immediate recall 2<sup>nd</sup> trial</td>
</tr>
<tr>
<td> Contrast<break/> 95% CI<break/> <italic>p</italic>-value</td>
<td>−1.3<break/>−2.8/0.3<break/>0.1047</td>
<td>−0.1<break/>−1.7/1.5<break/>0.8822</td>
<td>−1.3<break/>−2.9/0.2<break/>0.0970</td>
<td>−0.0<break/>−1.6/1.5<break/>0.9640</td>
<td>0.1<break/>−2.1/2.3<break/>0.9408</td>
</tr>
<tr>
<td colspan="6">Immediate recall 3<sup>rd</sup> trial</td>
</tr>
<tr>
<td> Contrast<break/> 95% CI<break/> <italic>p</italic>-value</td>
<td>−1.1<break/>−2.9/0.7<break/>0.2210</td>
<td>−1.0<break/>−2.8/0.8<break/>0.2702</td>
<td><bold>−2.7</bold><break/><bold>−4.5/−1.0</bold><break/><bold>0.0034</bold></td>
<td>−1.6<break/>−3.4/0.1<break/>0.0704</td>
<td>−0.6<break/>−3.2/1.9<break/>0.6206</td>
</tr>
<tr>
<td colspan="6">Delayed recall</td>
</tr>
<tr>
<td> Contrast<break/> 95% CI<break/> <italic>p</italic>-value</td>
<td>−9.90%<break/>−26.6/10.65%<break/>0.3135</td>
<td>11.31%<break/>−9.44/36.80%<break/>0.3020</td>
<td><bold>−25.5%</bold><break/><bold>−39.4/−8.42%</bold><break/><bold>0.0061</bold></td>
<td>−17.3%<break/>−32.7/1.56%<break/>0.0692</td>
<td><bold>−25.7%</bold><break/><bold>−44.5/−0.60%</bold><break/><bold>0.0456</bold></td>
</tr>
<tr>
<td colspan="6">Word recognition (correct)</td>
</tr>
<tr>
<td> Contrast<break/> 95% CI<break/> <italic>p</italic>-value</td>
<td>−0.82%<break/>−12.1/11.91%<break/>0.8923</td>
<td>2.24%<break/>−9.49/15.48%<break/>0.7169</td>
<td>−8.62%<break/>−19.1/3.22%<break/>0.1436</td>
<td>−7.87%<break/>−18.3/3.95%<break/>0.1790</td>
<td>−9.88%<break/>−24.1/6.97%<break/>0.2288</td>
</tr>
<tr>
<td colspan="6">Word recognition (incorrect)</td>
</tr>
<tr>
<td> Contrast<break/> 95% CI<break/> <italic>p</italic>-value</td>
<td>9.81%<break/>−24.6/59.91%<break/>0.6193</td>
<td>15.24%<break/>−21.9/70.03%<break/>0.4670</td>
<td>39.26%<break/>−4.69/103.5%<break/>0.0855</td>
<td>26.82%<break/>−12.3/83.41%<break/>0.2017</td>
<td>10.05%<break/>−35.6/88.10%<break/>0.7212</td>
</tr>
<tr>
<td colspan="6">Reaction time (correct)</td>
</tr>
<tr>
<td> Contrast<break/> 95% CI<break/> <italic>p</italic>-value</td>
<td>1.97%<break/>−4.70/9.11%<break/>0.5649</td>
<td>1.72%<break/>−4.98/8.90%<break/>0.6172</td>
<td>0.54%<break/>−6.08/7.64%<break/>0.8736</td>
<td>−1.40%<break/>−7.85/5.50%<break/>0.6775</td>
<td>−3.07%<break/>−11.9/6.70%<break/>0.5176</td>
</tr>
</tbody>
</table>
</table-wrap>
</sec>
<sec id="section22-0269881111431750">
<title>Pharmacodynamics of GSK598809</title>
<p>Following administration of GSK598809, transient increases in serum prolactin were observed (see <xref ref-type="fig" rid="fig9-0269881111431750">Figure 9</xref>). Peak prolactin levels, which increased much more in females than in males (<italic>p</italic> &lt; 0.0001), were reached roughly 3 hours after study drug administration and normalized within 12 hours. Administration of GSK598809 also caused a decrease in adaptive tracking performance, which was maximal between 2 and 6 hours after dose administration (see <xref ref-type="table" rid="table3-0269881111431750">Table 3</xref> and <xref ref-type="fig" rid="fig6-0269881111431750">Figure 6</xref>). No statistically significant effects were observed on any of the other pharmacodynamic parameters (see <xref ref-type="table" rid="table3-0269881111431750">Tables 3</xref>–<xref ref-type="table" rid="table5-0269881111431750">5</xref> and <xref ref-type="fig" rid="fig4-0269881111431750">Figures 4</xref>, <xref ref-type="fig" rid="fig4-0269881111431750">5</xref>, <xref ref-type="fig" rid="fig7-0269881111431750">7</xref> and <xref ref-type="fig" rid="fig8-0269881111431750">8</xref>).</p>
<fig id="fig9-0269881111431750" position="float">
<label>Figure 9.</label>
<caption>
<p>Time course of serum prolactin in female (left panel) and male subjects (right panel), following administration of GSK598809 capsules combined with alcohol infusion (open circles), GSK598809 capsules combined with placebo infusion (closed circles), placebo capsules combined with alcohol infusion (open triangles) and placebo capsules combined with placebo infusion (closed triangles). Means are presented with standard deviations as error bars.</p>
</caption>
<graphic xlink:href="10.1177_0269881111431750-fig9.tif"/>
</fig>
</sec>
<sec id="section23-0269881111431750">
<title>Pharmacodynamics of GSK598809 combined with alcohol</title>
<p>Co-administration of GSK598809 and alcohol resulted in additive effects on several pharmacodynamic parameters, compared with either treatment alone (see <xref ref-type="table" rid="table3-0269881111431750">Tables 3</xref>–<xref ref-type="table" rid="table3-0269881111431750">5</xref> and <xref ref-type="fig" rid="fig4-0269881111431750">Figures 4</xref>–<xref ref-type="fig" rid="fig8-0269881111431750">8</xref>). While the effects of administration of GSK598809 alone or alcohol alone on saccadic eye movements did not reach statistical significance, co-administration of GSK598809 and alcohol resulted in a significant impairment. No significant supra-additive effects were found on any of the pharmacodynamic parameters, except a small increase in saccadic reaction time (see <xref ref-type="table" rid="table3-0269881111431750">Table 3</xref>) and a small decrease in delayed word recall on the VVLT (see <xref ref-type="table" rid="table5-0269881111431750">Table 5</xref>).</p>
</sec></sec>
<sec id="section24-0269881111431750" sec-type="discussion">
<title>Discussion</title>
<p>The present study was performed to evaluate the pharmacokinetics and CNS effects of single oral doses of 175 mg of the novel dopamine D<sub>3</sub> receptor antagonist GSK598809 in healthy volunteers and possible interactions with alcohol. Within the present group of healthy volunteers, single doses of GSK598809 were generally well tolerated. The most frequent adverse effects were mild headache, dizziness, somnolence, nausea and vomiting. GSK598809 did not induce any significant extrapyramidal symptoms. Mild short-lasting akathisia was reported spontaneously once after administration of GSK598809, although this was not verified objectively by the Barnes Akathisia Rating Scale, when this was performed according to protocol. Plasma concentration of GSK598809 increased rapidly after oral administration (<italic>t</italic><sub>max</sub> of roughly 2–3 hours) and subsequently decreased in an apparent bi-exponential manner (terminal half-life of roughly 20 hours). No effect of GSK598809 on the pharmacokinetics of alcohol was observed, but alcohol decreased <italic>C</italic><sub>max</sub> and increased the AUC of GSK598809 to a limited extent, which is not considered to be of any clinical significance.</p>
<p>The CNS effects of GSK598809 alone were limited to an elevation of serum prolactin and a small decrease in adaptive tracking performance, with a time course that corresponds well with the observed pharmacokinetics. This study represents the first use of this pharmacodynamic test battery to evaluate the effects of a selective dopamine D<sub>3</sub> antagonist in healthy volunteers. As a result, no data of other dopamine D<sub>3</sub> receptor antagonists are available for comparison with the effects of GSK598809. Antipsychotic drugs (dopamine D<sub>2</sub> receptor antagonists) have been evaluated extensively with this pharmacodynamic test battery (<xref ref-type="bibr" rid="bibr13-0269881111431750">de Visser et al., 2001</xref>; <xref ref-type="bibr" rid="bibr33-0269881111431750">Liem-Moolenaar et al., 2010a</xref>, <xref ref-type="bibr" rid="bibr35-0269881111431750">2010b</xref>, <xref ref-type="bibr" rid="bibr34-0269881111431750">2011</xref>), but differences in tissue expression of D<sub>2</sub> and D<sub>3</sub> receptors and differences in receptor affinity profiles of the various drugs significantly limit the comparison of their effects to those of GSK598809.</p>
<p>Prolactin secretion by the lactotroph cells of the pituitary gland is under inhibitory control by dopamine, released predominantly from tuberoinfundibular dopaminergic neurons, acting on lactotrophic dopamine D<sub>2</sub> receptors (<xref ref-type="bibr" rid="bibr4-0269881111431750">Ben-Jonathan and Hnasko, 2001</xref>; <xref ref-type="bibr" rid="bibr15-0269881111431750">Freeman et al., 2000</xref>). Pharmacological blockade of dopamine D<sub>2</sub> receptors removes this inhibitory influence and subsequently increases prolactin levels. However, the role of dopamine D<sub>3</sub> receptor antagonism in the control of prolactin secretion is unknown. An autoradiographic study has demonstrated presence of D<sub>3</sub> receptors in the pituitary gland (<xref ref-type="bibr" rid="bibr20-0269881111431750">Herroelen et al., 1994</xref>), but the density was quite low and any possible role for dopamine D<sub>3</sub> receptors in the pituitary gland in endocrine function remains unclear. Alternatively, dopamine D<sub>3</sub> antagonism may cause prolactin elevation by acting at the level of the hypothalamus. The periventricular and arcuate nuclei of the hypothalamus constitute the origin of the tuberoinfundibular dopaminergic pathway, which projects to the median eminence, where dopamine is released into the hypophyseal portal vessels (<xref ref-type="bibr" rid="bibr38-0269881111431750">Moore and Bloom, 1978</xref>; <xref ref-type="bibr" rid="bibr1-0269881111431750">Albanese et al., 1986</xref>; <xref ref-type="bibr" rid="bibr4-0269881111431750">Ben-Jonathan and Hnasko, 2001</xref>). Hypothalamic expression of dopamine D<sub>3</sub> receptors has not yet been examined in full detail, but one study found no detectable levels in the arcuate nucleus, whereas the periventricular nucleus was not investigated (<xref ref-type="bibr" rid="bibr18-0269881111431750">Gurevich and Joyce, 1999</xref>). Therefore, any possible effect of dopamine D<sub>3</sub> antagonism on the hypothalamus, leading to prolactin elevation, also remains unclear. Another theoretical possibility is that GSK598809 could be acting on extra-dopaminergic mechanisms of prolactin control. However, a more likely explanation is that, despite a greater than 100-fold selectivity for D<sub>3</sub> receptors over D<sub>2</sub> receptors, GSK598809 at doses of 175 mg might cause enough D<sub>2</sub> receptor antagonism to modestly increase prolactin secretion.</p>
<p>The increases in serum prolactin following GSK598809 administration were much larger in female volunteers than in male volunteers (see <xref ref-type="fig" rid="fig9-0269881111431750">Figure 9</xref>). Similar gender differences in prolactin levels have been previously demonstrated after administration of typical antipsychotic drugs (<xref ref-type="bibr" rid="bibr37-0269881111431750">Meltzer and Fang, 1976</xref>; <xref ref-type="bibr" rid="bibr63-0269881111431750">Wode-Helgodt et al., 1977</xref>; <xref ref-type="bibr" rid="bibr36-0269881111431750">Meltzer et al., 1983</xref>; <xref ref-type="bibr" rid="bibr28-0269881111431750">Kuruvilla et al., 1992</xref>; <xref ref-type="bibr" rid="bibr51-0269881111431750">Smith et al., 2002</xref>) and atypical antipsychotic drugs (<xref ref-type="bibr" rid="bibr17-0269881111431750">Grunder et al., 1999</xref>; <xref ref-type="bibr" rid="bibr24-0269881111431750">Kinon et al., 2003</xref>; <xref ref-type="bibr" rid="bibr65-0269881111431750">Yasui-Furukori et al., 2010</xref>), which have been attributed to an enhanced responsiveness of lactotrophs to prolactin-releasing stimuli by females, compared with males, due to the effects of estrogens (<xref ref-type="bibr" rid="bibr8-0269881111431750">Buckman and Peake, 1973</xref>; <xref ref-type="bibr" rid="bibr9-0269881111431750">Buckman et al., 1976</xref>; <xref ref-type="bibr" rid="bibr43-0269881111431750">Petty, 1999</xref>; <xref ref-type="bibr" rid="bibr4-0269881111431750">Ben-Jonathan and Hnasko, 2001</xref>).</p>
<p>The other pharmacodynamic tests used in this study measure complex CNS functions. The neurophysiological and neurochemical mechanisms underlying these CNS functions have not yet been fully characterized, but are likely to involve multiple neurotransmitter receptor systems. The decrease in adaptive tracking performance after administration of GSK598809 indicates slight impairment in visuo-motor performance. Similar impairments in adaptive tracking performance have also been observed after administration of single doses of antipsychotic drugs (dopamine D<sub>2</sub> antagonists) such as haloperidol (<xref ref-type="bibr" rid="bibr33-0269881111431750">Liem-Moolenaar et al., 2010a</xref>) and risperidone (<xref ref-type="bibr" rid="bibr34-0269881111431750">Liem-Moolenaar et al., 2011</xref>) in healthy volunteers. However, unlike haloperidol and risperidone, GSK598809 did not affect smooth pursuit and saccadic eye movements, memory performance or any of the VAS. This clearly demonstrates the pharmacological distinctions between GSK598809 and antipsychotic drugs, but it is not necessarily an argument for D<sub>3</sub> receptor selectivity, since most antipsychotic drugs affect other neurotransmitter systems in addition to D<sub>2</sub> receptors. Recently, however, we examined the novel selective dopamine D<sub>2</sub> receptor antagonist JNJ-37822681 in healthy volunteers using similar pharmacodynamic tests (<xref ref-type="bibr" rid="bibr54-0269881111431750">te Beek et al., 2011b</xref>). Single oral doses of 15 mg JNJ-37822681 caused a reduction in adaptive tracking performance of about 2%, comparable to the 175 mg doses of GSK598809. Also, this dose of JNJ-37822681 caused about 60% D<sub>2</sub> receptor occupancy (<xref ref-type="bibr" rid="bibr53-0269881111431750">te Beek et al., 2011a</xref>) and produced prolactin elevations of more than 700% (<xref ref-type="bibr" rid="bibr54-0269881111431750">te Beek et al., 2011b</xref>), much larger than the 117% increase found with GSK598809 in this study. JNJ-37822681 also impaired saccadic and smooth pursuit eye movements (<xref ref-type="bibr" rid="bibr54-0269881111431750">te Beek et al., 2011b</xref>), which were unaffected by GSK598809. Although these indirect comparisons have their limitations, they provide at least some support for the <italic>in vivo</italic> selectivity of GSK598809 for dopamine D<sub>3</sub> receptors.</p>
<p>In addition to obtaining a dopamine D<sub>3</sub> receptor-mediated profile of CNS effects, our study was specifically designed to evaluate potential pharmacokinetic and pharmacodynamic interactions between GSK598809 and alcohol. An intravenous alcohol clamping paradigm was used to achieve pseudo-steady state levels of alcohol, which produced clear and expected CNS effects, similar to previously reported results of this alcohol clamping paradigm (<xref ref-type="bibr" rid="bibr67-0269881111431750">Zoethout et al., 2008</xref>, <xref ref-type="bibr" rid="bibr66-0269881111431750">2009</xref>). Co-administration of GSK598809 with intravenous alcohol levels at pseudo-steady state was generally well tolerated. However, somnolence and fatigue were reported more frequently, compared with the other treatments. Mild akathisia was reported spontaneously once, which was not verified objectively by the Barnes Akathisia Rating Scale, similar to the event after administration of GSK598809 alone. Co-administration of GSK598809 and alcohol generally produced additive CNS effects, without clear signs of supra- additive amplification of the effects of each treatment alone. Both GSK598809 and alcohol caused slight impairments of saccadic eye movements that failed to reach statistical significance by themselves, but the combination clearly differed from placebo. There was a small supra-additive increase in saccadic reaction time (see <xref ref-type="table" rid="table3-0269881111431750">Table 3</xref>) and there were also some indications that memory might be affected more by the combination than by each drug individually. These findings suggest that caution may be needed in the use of GSK598809 in individuals who consume alcohol moderately or excessively, although the effects will probably be dominated by alcohol.</p>
<p>In conclusion, the present study demonstrates elevation of serum prolactin and a small decrease in adaptive tracking performance after administration of the novel selective dopamine D<sub>3</sub> receptor antagonist GSK598809 within a small group of healthy volunteers. An interaction with intravenous alcohol infusion at pseudo-steady state was demonstrated, resulting in a decreased <italic>C</italic><sub>max</sub> and increased AUC of GSK598809 and mainly additive effects on several CNS parameters. Although somnolence and fatigue were reported more frequently, the combination was generally well tolerated by healthy volunteers.</p>
</sec>
</body>
<back>
<sec id="section25-0269881111431750">
<title>Funding</title>
<p>This study was sponsored by GlaxoSmithKline Research &amp; Development Limited, Verona, Italy.</p>
</sec>
<sec id="section26-0269881111431750">
<title>Conflict of interest</title>
<p>Massimo Bani, Anne Andorn, Laura Iavarone and Paolo Fina were employees of GlaxoSmithKline Research &amp; Development Limited, Verona, Italy, when this work was performed. Erik te Beek, Remco Zoethout, Erica Klaassen and Joop van Gerven are employees of the Centre for Human Drug Research, Leiden, The Netherlands.</p>
</sec>
<ref-list>
<title>References</title>
<ref id="bibr1-0269881111431750">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Albanese</surname><given-names>A</given-names></name>
<name><surname>Altavista</surname><given-names>MC</given-names></name>
<name><surname>Rossi</surname><given-names>P</given-names></name>
</person-group> (<year>1986</year>) <article-title>Organization of central nervous system dopaminergic pathways</article-title>. <source>J Neural Transm Suppl</source> <volume>22</volume>: <fpage>3</fpage>-<lpage>17</lpage>.</citation>
</ref>
<ref id="bibr2-0269881111431750">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Baloh</surname><given-names>RW</given-names></name>
<name><surname>Sills</surname><given-names>AW</given-names></name>
<name><surname>Kumley</surname><given-names>WE</given-names></name>
<name><surname>Honrubia</surname><given-names>V</given-names></name>
</person-group> (<year>1975</year>) <article-title>Quantitative measurement of saccade amplitude, duration, and velocity</article-title>. <source>Neurology</source> <volume>25</volume>: <fpage>1065</fpage>–<lpage>1070</lpage>.</citation>
</ref>
<ref id="bibr3-0269881111431750">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Barnes</surname><given-names>TR</given-names></name>
</person-group> (<year>1989</year>) <article-title>A rating scale for drug-induced akathisia</article-title>. <source>Br J Psychiatry</source> <volume>154</volume>: <fpage>672</fpage>–<lpage>676</lpage>.</citation>
</ref>
<ref id="bibr4-0269881111431750">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Ben-Jonathan</surname><given-names>N</given-names></name>
<name><surname>Hnasko</surname><given-names>R</given-names></name>
</person-group> (<year>2001</year>) <article-title>Dopamine as a prolactin (PRL) inhibitor</article-title>. <source>Endocr Rev</source> <volume>22</volume>: <fpage>724</fpage>–<lpage>763</lpage>.</citation>
</ref>
<ref id="bibr5-0269881111431750">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Bittencourt</surname><given-names>PR</given-names></name>
<name><surname>Wade</surname><given-names>P</given-names></name>
<name><surname>Smith</surname><given-names>AT</given-names></name>
<name><surname>Richens</surname><given-names>A</given-names></name>
</person-group> (<year>1983</year>) <article-title>Benzodiazepines impair smooth pursuit eye movements</article-title>. <source>Br J Clin Pharmacol</source> <volume>15</volume>: <fpage>259</fpage>–<lpage>262</lpage>.</citation>
</ref>
<ref id="bibr6-0269881111431750">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Bond</surname><given-names>A</given-names></name>
<name><surname>Lader</surname><given-names>M</given-names></name>
</person-group> (<year>1974</year>) <article-title>Use of analog scales in rating subjective feelings</article-title>. <source>Br J Med Psychol</source> <volume>47</volume>(<issue>SEP</issue>): <fpage>211</fpage>–<lpage>218</lpage>.</citation>
</ref>
<ref id="bibr7-0269881111431750">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Borland</surname><given-names>RG</given-names></name>
<name><surname>Nicholson</surname><given-names>AN</given-names></name>
</person-group> (<year>1984</year>) <article-title>Visual motor co-ordination and dynamic visual acuity</article-title>. <source>Br J Clin Pharmacol</source> <volume>18</volume>(<supplement>Suppl. 1</supplement>): <fpage>69S</fpage>-<lpage>72S</lpage>.</citation>
</ref>
<ref id="bibr8-0269881111431750">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Buckman</surname><given-names>MT</given-names></name>
<name><surname>Peake</surname><given-names>GT</given-names></name>
</person-group> (<year>1973</year>) <article-title>Estrogen potentiation of phenothiazine-induced prolactin secretion in man</article-title>. <source>J Clin Endocrinol Metab</source> <volume>37</volume>: <fpage>977</fpage>–<lpage>980</lpage>.</citation>
</ref>
<ref id="bibr9-0269881111431750">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Buckman</surname><given-names>MT</given-names></name>
<name><surname>Peake</surname><given-names>GT</given-names></name>
<name><surname>Srivastava</surname><given-names>LS</given-names></name>
</person-group> (<year>1976</year>) <article-title>Endogenous estrogen modulates phenothiazine stimulated prolactin secretion</article-title>. <source>J Clin Endocrinol Metab</source> <volume>43</volume>: <fpage>901</fpage>–<lpage>906</lpage>.</citation>
</ref>
<ref id="bibr10-0269881111431750">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Caine</surname><given-names>SB</given-names></name>
<name><surname>Koob</surname><given-names>GF</given-names></name>
</person-group> (<year>1993</year>) <article-title>Modulation of cocaine self-administration in the rat through D-3 dopamine receptors</article-title>. <source>Science</source> <volume>260</volume>: <fpage>1814</fpage>–<lpage>1816</lpage>.</citation>
</ref>
<ref id="bibr11-0269881111431750">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Cami</surname><given-names>J</given-names></name>
<name><surname>Farre</surname><given-names>M</given-names></name>
</person-group> (<year>2003</year>) <article-title>Drug addiction</article-title>. <source>N Engl J Med</source> <volume>349</volume>(<issue>10</issue>): <fpage>975</fpage>–<lpage>986</lpage>.</citation>
</ref>
<ref id="bibr12-0269881111431750">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>de Haas</surname><given-names>SL</given-names></name>
<name><surname>Franson</surname><given-names>KL</given-names></name>
<name><surname>Schmitt</surname><given-names>JA</given-names></name><etal/>
</person-group>. (<year>2009</year>) <article-title>The pharmacokinetic and pharmacodynamic effects of SL65.1498, a GABA-A alpha2,3 selective agonist, in comparison with lorazepam in healthy volunteers</article-title>. <source>J Psychopharmacol</source> <volume>23</volume>: <fpage>625</fpage>–<lpage>632</lpage>.</citation>
</ref>
<ref id="bibr13-0269881111431750">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>de Visser</surname><given-names>SJ</given-names></name>
<name><surname>van der Post</surname><given-names>J</given-names></name>
<name><surname>Pieters</surname><given-names>MS</given-names></name>
<name><surname>Cohen</surname><given-names>AF</given-names></name>
<name><surname>van Gerven</surname><given-names>JM</given-names></name>
</person-group> (<year>2001</year>) <article-title>Biomarkers for the effects of antipsychotic drugs in healthy volunteers</article-title>. <source>Br J Clin Pharmacol</source> <volume>51</volume>: <fpage>119</fpage>–<lpage>132</lpage>.</citation>
</ref>
<ref id="bibr14-0269881111431750">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Di Chiara</surname><given-names>G</given-names></name>
<name><surname>Imperato</surname><given-names>A</given-names></name>
</person-group> (<year>1988</year>) <article-title>Drugs abused by humans preferentially increase synaptic dopamine concentrations in the mesolimbic system of freely moving rats</article-title>. <source>Proc Natl Acad Sci U S A</source> <volume>85</volume>(<issue>14</issue>): <fpage>5274</fpage>–<lpage>5278</lpage>.</citation>
</ref>
<ref id="bibr15-0269881111431750">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Freeman</surname><given-names>ME</given-names></name>
<name><surname>Kanyicska</surname><given-names>B</given-names></name>
<name><surname>Lerant</surname><given-names>A</given-names></name>
<name><surname>Nagy</surname><given-names>G</given-names></name>
</person-group> (<year>2000</year>) <article-title>Prolactin: structure, function, and regulation of secretion</article-title>. <source>Physiol Rev</source> <volume>80</volume>: <fpage>1523</fpage>–<lpage>1631</lpage>.</citation>
</ref>
<ref id="bibr16-0269881111431750">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Gijsman</surname><given-names>HJ</given-names></name>
<name><surname>van Gerven</surname><given-names>JM</given-names></name>
<name><surname>Tieleman</surname><given-names>MC</given-names></name><etal/>
</person-group>. (<year>1998</year>) <article-title>Pharmacokinetic and pharmacodynamic profile of oral and intravenous meta-chlorophenylpiperazine in healthy volunteers</article-title>. <source>J Clin Psychopharmacol</source> <volume>18</volume>: <fpage>289</fpage>–<lpage>295</lpage>.</citation>
</ref>
<ref id="bibr17-0269881111431750">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Grunder</surname><given-names>G</given-names></name>
<name><surname>Wetzel</surname><given-names>H</given-names></name>
<name><surname>Schlosser</surname><given-names>R</given-names></name><etal/>
</person-group>. (<year>1999</year>) <article-title>Neuroendocrine response to antipsychotics: effects of drug type and gender</article-title>. <source>Biol Psychiatry</source> <volume>45</volume>: <fpage>89</fpage>–<lpage>97</lpage>.</citation>
</ref>
<ref id="bibr18-0269881111431750">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Gurevich</surname><given-names>EV</given-names></name>
<name><surname>Joyce</surname><given-names>JN</given-names></name>
</person-group> (<year>1999</year>) <article-title>Distribution of dopamine D<sub>3</sub> receptor expressing neurons in the human forebrain: comparison with D<sub>2</sub> receptor expressing neurons</article-title>. <source>Neuropsychopharmacology</source> <volume>20</volume>: <fpage>60</fpage>–<lpage>80</lpage>.</citation>
</ref>
<ref id="bibr19-0269881111431750">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Heidbreder</surname><given-names>CA</given-names></name>
<name><surname>Gardner</surname><given-names>EL</given-names></name>
<name><surname>Xi</surname><given-names>ZX</given-names></name><etal/>
</person-group>. (<year>2005</year>) <article-title>The role of central dopamine D<sub>3</sub> receptors in drug addiction: a review of pharmacological evidence</article-title>. <source>Brain Res Brain Res Rev</source> <volume>49</volume>: <fpage>77</fpage>–<lpage>105</lpage>.</citation>
</ref>
<ref id="bibr20-0269881111431750">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Herroelen</surname><given-names>L</given-names></name>
<name><surname>De Backer</surname><given-names>JP</given-names></name>
<name><surname>Wilczak</surname><given-names>N</given-names></name>
<name><surname>Flamez</surname><given-names>A</given-names></name>
<name><surname>Vauquelin</surname><given-names>G</given-names></name>
<name><surname>De Keyser</surname><given-names>J</given-names></name>
</person-group> (<year>1994</year>) <article-title>Autoradiographic distribution of D<sub>3</sub>-type dopamine receptors in human brain using [<sup>3</sup>H]7-hydroxy-<italic>N,N</italic>-di-<italic>n</italic>-propyl-2-aminotetralin</article-title>. <source>Brain Res</source> <volume>648</volume>: <fpage>222</fpage>–<lpage>228</lpage>.</citation>
</ref>
<ref id="bibr21-0269881111431750">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Hyman</surname><given-names>SE</given-names></name>
</person-group> (<year>2005</year>) <article-title>Addiction: a disease of learning and memory</article-title>. <source>Am J Psychiatry</source> <volume>162</volume>: <fpage>1414</fpage>–<lpage>1422</lpage>.</citation>
</ref>
<ref id="bibr22-0269881111431750">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Hyman</surname><given-names>SE</given-names></name>
<name><surname>Malenka</surname><given-names>RC</given-names></name>
</person-group> (<year>2001</year>) <article-title>Addiction and the brain: the neurobiology of compulsion and its persistence</article-title>. <source>Nat Rev Neurosci</source> <volume>2</volume>: <fpage>695</fpage>–<lpage>703</lpage>.</citation>
</ref>
<ref id="bibr23-0269881111431750">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Joyce</surname><given-names>JN</given-names></name>
<name><surname>Millan</surname><given-names>MJ</given-names></name>
</person-group> (<year>2005</year>) <article-title>Dopamine D<sub>3</sub> receptor antagonists as therapeutic agents</article-title>. <source>Drug Discov Today</source> <volume>10</volume>: <fpage>917</fpage>–<lpage>925</lpage>.</citation>
</ref>
<ref id="bibr24-0269881111431750">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Kinon</surname><given-names>BJ</given-names></name>
<name><surname>Gilmore</surname><given-names>JA</given-names></name>
<name><surname>Liu</surname><given-names>H</given-names></name>
<name><surname>Halbreich</surname><given-names>UM</given-names></name>
</person-group> (<year>2003</year>) <article-title>Hyperprolactinemia in response to antipsychotic drugs: characterization across comparative clinical trials</article-title>. <source>Psychoneuroendocrinology</source> <volume>28</volume>(<supplement>Suppl. 2</supplement>): <fpage>69</fpage>–<lpage>82</lpage>.</citation>
</ref>
<ref id="bibr25-0269881111431750">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Koob</surname><given-names>GF</given-names></name>
<name><surname>Bloom</surname><given-names>FE</given-names></name>
</person-group> (<year>1988</year>) <article-title>Cellular and molecular mechanisms of drug dependence</article-title>. <source>Science</source> <volume>242</volume>: <fpage>715</fpage>–<lpage>723</lpage>.</citation>
</ref>
<ref id="bibr26-0269881111431750">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Koob</surname><given-names>GF</given-names></name>
<name><surname>Nestler</surname><given-names>EJ</given-names></name>
</person-group> (<year>1997</year>) <article-title>The neurobiology of drug addiction</article-title>. <source>J Neuropsychiatry Clin Neurosci</source> <volume>9</volume>: <fpage>482</fpage>–<lpage>497</lpage>.</citation>
</ref>
<ref id="bibr27-0269881111431750">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Koob</surname><given-names>GF</given-names></name>
<name><surname>Sanna</surname><given-names>PP</given-names></name>
<name><surname>Bloom</surname><given-names>FE</given-names></name>
</person-group> (<year>1998</year>) <article-title>Neuroscience of addiction</article-title>. <source>Neuron</source> <volume>21</volume>(<issue>3</issue>): <fpage>467</fpage>–<lpage>476</lpage>.</citation>
</ref>
<ref id="bibr28-0269881111431750">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Kuruvilla</surname><given-names>A</given-names></name>
<name><surname>Peedicayil</surname><given-names>J</given-names></name>
<name><surname>Srikrishna</surname><given-names>G</given-names></name>
<name><surname>Kuruvilla</surname><given-names>K</given-names></name>
<name><surname>Kanagasabapathy</surname><given-names>AS</given-names></name>
</person-group> (<year>1992</year>) <article-title>A study of serum prolactin levels in schizophrenia: comparison of males and females</article-title>. <source>Clin Exp Pharmacol Physiol</source> <volume>19</volume>: <fpage>603</fpage>–<lpage>606</lpage>.</citation>
</ref>
<ref id="bibr29-0269881111431750">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Landwehrmeyer</surname><given-names>B</given-names></name>
<name><surname>Mengod</surname><given-names>G</given-names></name>
<name><surname>Palacios</surname><given-names>JM</given-names></name>
</person-group> (<year>1993</year>) <article-title>Dopamine D<sub>3</sub> receptor mRNA and binding sites in human brain</article-title>. <source>Brain Res Mol Brain Res</source> <volume>18</volume>: <fpage>187</fpage>–<lpage>192</lpage>.</citation>
</ref>
<ref id="bibr30-0269881111431750">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Le Foll</surname><given-names>B</given-names></name>
<name><surname>Goldberg</surname><given-names>SR</given-names></name>
<name><surname>Sokoloff</surname><given-names>P</given-names></name>
</person-group> (<year>2005</year>) <article-title>The dopamine D<sub>3</sub> receptor and drug dependence: effects on reward or beyond?</article-title> <source>Neuropharmacology</source> <volume>49</volume>: <fpage>525</fpage>–<lpage>541</lpage>.</citation>
</ref>
<ref id="bibr31-0269881111431750">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Levant</surname><given-names>B</given-names></name>
</person-group> (<year>1997</year>) <article-title>The D<sub>3</sub> dopamine receptor: neurobiology and potential clinical relevance</article-title>. <source>Pharmacol Rev</source> <volume>49</volume>: <fpage>231</fpage>–<lpage>252</lpage>.</citation>
</ref>
<ref id="bibr32-0269881111431750">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Lieber</surname><given-names>CS</given-names></name>
</person-group> (<year>1997</year>) <article-title>Cytochrome P-4502E1: its physiological and pathological role</article-title>. <source>Physiol Rev</source> <volume>77</volume>: <fpage>517</fpage>–<lpage>544</lpage>.</citation>
</ref>
<ref id="bibr33-0269881111431750">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Liem-Moolenaar</surname><given-names>M</given-names></name>
<name><surname>Gray</surname><given-names>FA</given-names></name>
<name><surname>de Visser</surname><given-names>SJ</given-names></name><etal/>
</person-group>. (<year>2010a</year>) <article-title>Psychomotor and cognitive effects of a single oral dose of talnetant (SB223412) in healthy volunteers compared with placebo or haloperidol</article-title>. <source>J Psychopharmacol</source> <volume>24</volume>: <fpage>73</fpage>–<lpage>82</lpage>.</citation>
</ref>
<ref id="bibr34-0269881111431750">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Liem-Moolenaar</surname><given-names>M</given-names></name>
<name><surname>Rad</surname><given-names>M</given-names></name>
<name><surname>Zamuner</surname><given-names>S</given-names></name><etal/>
</person-group>. (<year>2011</year>) <article-title>Central nervous system effects of the interaction between risperidone (single dose) and the 5HT6 antagonist SB742457 (repeated doses) in healthy males</article-title>. <source>Br J Clin Pharmacol</source> <volume>71</volume>: <fpage>907</fpage>–<lpage>916</lpage>.</citation>
</ref>
<ref id="bibr35-0269881111431750">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Liem-Moolenaar</surname><given-names>M</given-names></name>
<name><surname>te Beek</surname><given-names>ET</given-names></name>
<name><surname>de Kam</surname><given-names>ML</given-names></name><etal/>
</person-group>. (<year>2010b</year>) <article-title>Central nervous system effects of haloperidol on THC in healthy male volunteers</article-title>. <source>J Psychopharmacol</source> <volume>24</volume>: <fpage>1697</fpage>–<lpage>1708</lpage>.</citation>
</ref>
<ref id="bibr36-0269881111431750">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Meltzer</surname><given-names>HY</given-names></name>
<name><surname>Busch</surname><given-names>DA</given-names></name>
<name><surname>Fang</surname><given-names>VS</given-names></name>
</person-group> (<year>1983</year>) <article-title>Serum neuroleptic and prolactin levels in schizophrenic patients and clinical response</article-title>. <source>Psychiatry Res</source> <volume>9</volume>: <fpage>271</fpage>–<lpage>283</lpage>.</citation>
</ref>
<ref id="bibr37-0269881111431750">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Meltzer</surname><given-names>HY</given-names></name>
<name><surname>Fang</surname><given-names>VS</given-names></name>
</person-group> (<year>1976</year>) <article-title>The effect of neuroleptics on serum prolactin in schizophrenic patients</article-title>. <source>Arch Gen Psychiatry</source> <volume>33</volume>: <fpage>279</fpage>–<lpage>286</lpage>.</citation>
</ref>
<ref id="bibr38-0269881111431750">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Moore</surname><given-names>RY</given-names></name>
<name><surname>Bloom</surname><given-names>FE</given-names></name>
</person-group> (<year>1978</year>) <article-title>Central catecholamine neuron systems: anatomy and physiology of the dopamine systems</article-title>. <source>Annu Rev Neurosci</source> <volume>1</volume>: <fpage>129</fpage>–<lpage>169</lpage>.</citation>
</ref>
<ref id="bibr39-0269881111431750">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Munetz</surname><given-names>MR</given-names></name>
<name><surname>Benjamin</surname><given-names>S</given-names></name>
</person-group> (<year>1988</year>) <article-title>How to examine patients using the Abnormal Involuntary Movement Scale</article-title>. <source>Hosp Community Psychiatry</source> <volume>39</volume>: <fpage>1172</fpage>–<lpage>1177</lpage>.</citation>
</ref>
<ref id="bibr40-0269881111431750">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Murray</surname><given-names>AM</given-names></name>
<name><surname>Ryoo</surname><given-names>HL</given-names></name>
<name><surname>Gurevich</surname><given-names>E</given-names></name>
<name><surname>Joyce</surname><given-names>JN</given-names></name>
</person-group> (<year>1994</year>) <article-title>Localization of dopamine D<sub>3</sub> receptors to mesolimbic and D<sub>2</sub> receptors to mesostriatal regions of human forebrain</article-title>. <source>Proc Natl Acad Sci U S A</source> <volume>91</volume>: <fpage>11271</fpage>–<lpage>11275</lpage>.</citation>
</ref>
<ref id="bibr41-0269881111431750">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Nestler</surname><given-names>EJ</given-names></name>
</person-group> (<year>2005</year>) <article-title>Is there a common molecular pathway for addiction?</article-title> <source>Nat Neurosci</source> <volume>8</volume>: <fpage>1445</fpage>–<lpage>1449</lpage>.</citation>
</ref>
<ref id="bibr42-0269881111431750">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Norris</surname><given-names>H</given-names></name>
</person-group> (<year>1971</year>) <article-title>The action of sedatives on brain stem oculomotor systems in man</article-title>. <source>Neuropharmacology</source> <volume>10</volume>: <fpage>181</fpage>–<lpage>191</lpage>.</citation>
</ref>
<ref id="bibr43-0269881111431750">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Petty</surname><given-names>RG</given-names></name>
</person-group> (<year>1999</year>) <article-title>Prolactin and antipsychotic medications: mechanism of action</article-title>. <source>Schizophr Res</source> <volume>35</volume>(<supplement>Suppl.</supplement>): <fpage>S67</fpage>-<lpage>S73</lpage>.</citation>
</ref>
<ref id="bibr44-0269881111431750">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Pierce</surname><given-names>RC</given-names></name>
<name><surname>Kumaresan</surname><given-names>V</given-names></name>
</person-group> (<year>2006</year>) <article-title>The mesolimbic dopamine system: the final common pathway for the reinforcing effect of drugs of abuse?</article-title> <source>Neurosci Biobehav Rev</source> <volume>30</volume>: <fpage>215</fpage>–<lpage>238</lpage>.</citation>
</ref>
<ref id="bibr45-0269881111431750">
<citation citation-type="book">
<person-group person-group-type="author">
<name><surname>Rey</surname><given-names>A</given-names></name>
</person-group> (<year>1964</year>) <source>L’examen clinique en psychologie</source>. <publisher-loc>Paris</publisher-loc>: <publisher-name>Presses Universitaires de France</publisher-name>.</citation>
</ref>
<ref id="bibr46-0269881111431750">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Schmitt</surname><given-names>JA</given-names></name>
<name><surname>Jorissen</surname><given-names>BL</given-names></name>
<name><surname>Sobczak</surname><given-names>S</given-names></name><etal/>
</person-group>. (<year>2000</year>) <article-title>Tryptophan depletion impairs memory consolidation but improves focussed attention in healthy young volunteers</article-title>. <source>J Psychopharmacol</source> <volume>14</volume>: <fpage>21</fpage>–<lpage>29</lpage>.</citation>
</ref>
<ref id="bibr47-0269881111431750">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Searle</surname><given-names>G</given-names></name>
<name><surname>Beaver</surname><given-names>JD</given-names></name>
<name><surname>Comley</surname><given-names>RA</given-names></name><etal/>
</person-group>. (<year>2010</year>) <article-title>Imaging dopamine D<sub>3</sub> receptors in the human brain with positron emission tomography, [<sup>11</sup>C]PHNO, and a selective D<sub>3</sub> receptor antagonist</article-title>. <source>Biol Psychiatry</source> <volume>68</volume>: <fpage>392</fpage>–<lpage>399</lpage>.</citation>
</ref>
<ref id="bibr48-0269881111431750">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Seeman</surname><given-names>P</given-names></name>
<name><surname>Wilson</surname><given-names>A</given-names></name>
<name><surname>Gmeiner</surname><given-names>P</given-names></name>
<name><surname>Kapur</surname><given-names>S</given-names></name>
</person-group> (<year>2006</year>) <article-title>Dopamine D2 and D3 receptors in human putamen, caudate nucleus, and globus pallidus</article-title>. <source>Synapse</source> <volume>60</volume>: <fpage>205</fpage>–<lpage>211</lpage>.</citation>
</ref>
<ref id="bibr49-0269881111431750">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Segal</surname><given-names>DM</given-names></name>
<name><surname>Moraes</surname><given-names>CT</given-names></name>
<name><surname>Mash</surname><given-names>DC</given-names></name>
</person-group> (<year>1997</year>) <article-title>Up-regulation of D<sub>3</sub> dopamine receptor mRNA in the nucleus accumbens of human cocaine fatalities</article-title>. <source>Brain Res Mol Brain Res</source> <volume>45</volume>: <fpage>335</fpage>–<lpage>339</lpage>.</citation>
</ref>
<ref id="bibr50-0269881111431750">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Simpson</surname><given-names>GM</given-names></name>
<name><surname>Angus</surname><given-names>JW</given-names></name>
</person-group> (<year>1970</year>) <article-title>A rating scale for extrapyramidal side effects</article-title>. <source>Acta Psychiatr Scand Suppl</source> <volume>212</volume>: <fpage>11</fpage>–<lpage>19</lpage>.</citation>
</ref>
<ref id="bibr51-0269881111431750">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Smith</surname><given-names>S</given-names></name>
<name><surname>Wheeler</surname><given-names>MJ</given-names></name>
<name><surname>Murray</surname><given-names>R</given-names></name>
<name><surname>O’Keane</surname><given-names>V</given-names></name>
</person-group> (<year>2002</year>) <article-title>The effects of antipsychotic-induced hyperprolactinaemia on the hypothalamic-pituitary-gonadal axis</article-title>. <source>J Clin Psychopharmacol</source> <volume>22</volume>: <fpage>109</fpage>–<lpage>114</lpage>.</citation>
</ref>
<ref id="bibr52-0269881111431750">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Staley</surname><given-names>JK</given-names></name>
<name><surname>Mash</surname><given-names>DC</given-names></name>
</person-group> (<year>1996</year>) <article-title>Adaptive increase in D<sub>3</sub> dopamine receptors in the brain reward circuits of human cocaine fatalities</article-title>. <source>J Neurosci</source> <volume>16</volume>: <fpage>6100</fpage>–<lpage>6106</lpage>.</citation>
</ref>
<ref id="bibr53-0269881111431750">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>te Beek</surname><given-names>ET</given-names></name>
<name><surname>De Boer</surname><given-names>P</given-names></name>
<name><surname>Moerland</surname><given-names>M</given-names></name>
<name><surname>Schmidt</surname><given-names>ME</given-names></name>
<name><surname>Hoetjes</surname><given-names>NJ</given-names></name>
<name><surname>Windhorst</surname><given-names>AD</given-names></name><etal/>
</person-group>. (<year>2011a</year>) <article-title>In vivo quantification of striatal dopamine D2 receptor occupancy by JNJ-37822681 using [11C] raclopride and positron emission tomography. Accepted for publication</article-title> in <source>Journal of Psychopharmacology</source>.</citation>
</ref>
<ref id="bibr54-0269881111431750">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>te Beek</surname><given-names>ET</given-names></name>
<name><surname>Moerland</surname><given-names>M</given-names></name>
<name><surname>De Boer</surname><given-names>P</given-names></name>
<name><surname>Van Nueten</surname><given-names>L</given-names></name>
<name><surname>De Kam</surname><given-names>ML</given-names></name>
<name><surname>Burggraaf</surname><given-names>J</given-names></name><etal/>
</person-group>. (<year>2011b</year>) <article-title>Pharmacokinetics and central nervous system effects of the novel dopamine D2 receptor antagonist JNJ-37822681</article-title>. <source>Journal of Psychopharmacology</source>.</citation>
</ref>
<ref id="bibr55-0269881111431750">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>van Steveninck</surname><given-names>AL</given-names></name>
<name><surname>Gieschke</surname><given-names>R</given-names></name>
<name><surname>Schoemaker</surname><given-names>HC</given-names></name><etal/>
</person-group>. (<year>1993</year>) <article-title>Pharmacodynamic interactions of diazepam and intravenous alcohol at pseudo steady state</article-title>. <source>Psychopharmacology (Berl)</source> <volume>110</volume>: <fpage>471</fpage>–<lpage>478</lpage>.</citation>
</ref>
<ref id="bibr56-0269881111431750">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>van Steveninck</surname><given-names>AL</given-names></name>
<name><surname>Schoemaker</surname><given-names>HC</given-names></name>
<name><surname>Pieters</surname><given-names>MS</given-names></name>
<name><surname>Kroon</surname><given-names>R</given-names></name>
<name><surname>Breimer</surname><given-names>DD</given-names></name>
<name><surname>Cohen</surname><given-names>AF</given-names></name>
</person-group> (<year>1991</year>) <article-title>A comparison of the sensitivities of adaptive tracking, eye movement analysis and visual analog lines to the effects of incremental doses of temazepam in healthy volunteers</article-title>. <source>Clin Pharmacol Ther</source> <volume>50</volume>: <fpage>172</fpage>–<lpage>180</lpage>.</citation>
</ref>
<ref id="bibr57-0269881111431750">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>van Steveninck</surname><given-names>AL</given-names></name>
<name><surname>van Berckel</surname><given-names>BN</given-names></name>
<name><surname>Schoemaker</surname><given-names>RC</given-names></name>
<name><surname>Breimer</surname><given-names>DD</given-names></name>
<name><surname>van Gerven</surname><given-names>JM</given-names></name>
<name><surname>Cohen</surname><given-names>AF</given-names></name>
</person-group> (<year>1999</year>) <article-title>The sensitivity of pharmacodynamic tests for the central nervous system effects of drugs on the effects of sleep deprivation</article-title>. <source>J Psychopharmacol</source> <volume>13</volume>: <fpage>10</fpage>–<lpage>17</lpage>.</citation>
</ref>
<ref id="bibr58-0269881111431750">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Volkow</surname><given-names>ND</given-names></name>
<name><surname>Fowler</surname><given-names>JS</given-names></name>
<name><surname>Wang</surname><given-names>GJ</given-names></name>
</person-group> (<year>1999</year>) <article-title>Imaging studies on the role of dopamine in cocaine reinforcement and addiction in humans</article-title>. <source>J Psychopharmacol</source> <volume>13</volume>: <fpage>337</fpage>–<lpage>345</lpage>.</citation>
</ref>
<ref id="bibr59-0269881111431750">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Volkow</surname><given-names>ND</given-names></name>
<name><surname>Fowler</surname><given-names>JS</given-names></name>
<name><surname>Wang</surname><given-names>GJ</given-names></name>
</person-group> (<year>2003</year>) <article-title>Positron emission tomography and single-photon emission computed tomography in substance abuse research</article-title>. <source>Semin Nucl Med</source> <volume>33</volume>: <fpage>114</fpage>–<lpage>128</lpage>.</citation>
</ref>
<ref id="bibr60-0269881111431750">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Volkow</surname><given-names>ND</given-names></name>
<name><surname>Fowler</surname><given-names>JS</given-names></name>
<name><surname>Wang</surname><given-names>GJ</given-names></name>
<name><surname>Baler</surname><given-names>R</given-names></name>
<name><surname>Telang</surname><given-names>F</given-names></name>
</person-group> (<year>2009</year>) <article-title>Imaging dopamine’s role in drug abuse and addiction</article-title>. <source>Neuropharmacology</source> <volume>56</volume>(<supplement>Suppl. 1</supplement>): <fpage>3</fpage>–<lpage>8</lpage>.</citation>
</ref>
<ref id="bibr61-0269881111431750">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Volkow</surname><given-names>ND</given-names></name>
<name><surname>Fowler</surname><given-names>JS</given-names></name>
<name><surname>Wang</surname><given-names>GJ</given-names></name>
<name><surname>Swanson</surname><given-names>JM</given-names></name>
</person-group> (<year>2004</year>) <article-title>Dopamine in drug abuse and addiction: results from imaging studies and treatment implications</article-title>. <source>Mol Psychiatry</source> <volume>9</volume>: <fpage>557</fpage>–<lpage>569</lpage>.</citation>
</ref>
<ref id="bibr62-0269881111431750">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Volkow</surname><given-names>ND</given-names></name>
<name><surname>Fowler</surname><given-names>JS</given-names></name>
<name><surname>Wang</surname><given-names>GJ</given-names></name>
<name><surname>Swanson</surname><given-names>JM</given-names></name>
<name><surname>Telang</surname><given-names>F</given-names></name>
</person-group> (<year>2007</year>) <article-title>Dopamine in drug abuse and addiction: results of imaging studies and treatment implications</article-title>. <source>Arch Neurol</source> <volume>64</volume>: <fpage>1575</fpage>–<lpage>1579</lpage>.</citation>
</ref>
<ref id="bibr63-0269881111431750">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Wode-Helgodt</surname><given-names>B</given-names></name>
<name><surname>Eneroth</surname><given-names>P</given-names></name>
<name><surname>Fyro</surname><given-names>B</given-names></name>
<name><surname>Gullberg</surname><given-names>B</given-names></name>
<name><surname>Sedvall</surname><given-names>G</given-names></name>
</person-group> (<year>1977</year>) <article-title>Effect of chlorpromazine treatment on prolactin levels in cerebrospinal fluid and plasma of psychotic patients</article-title>. <source>Acta Psychiatr Scand</source> <volume>56</volume>: <fpage>280</fpage>–<lpage>293</lpage>.</citation>
</ref>
<ref id="bibr64-0269881111431750">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Wright</surname><given-names>BM</given-names></name>
</person-group> (<year>1971</year>) <article-title>A simple mechanical ataxia-meter</article-title>. <source>J Physiol</source> <volume>218</volume>(<issue>1</issue>): <fpage>27P</fpage>-<lpage>28P</lpage>.</citation>
</ref>
<ref id="bibr65-0269881111431750">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Yasui-Furukori</surname><given-names>N</given-names></name>
<name><surname>Saito</surname><given-names>M</given-names></name>
<name><surname>Nakagami</surname><given-names>T</given-names></name><etal/>
</person-group>. (<year>2010</year>) <article-title>Gender-specific prolactin response to antipsychotic treatments with risperidone and olanzapine and its relationship to drug concentrations in patients with acutely exacerbated schizophrenia</article-title>. <source>Prog Neuropsychopharmacol Biol Psychiatry</source> <volume>34</volume>: <fpage>537</fpage>–<lpage>540</lpage>.</citation>
</ref>
<ref id="bibr66-0269881111431750">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Zoethout</surname><given-names>RW</given-names></name>
<name><surname>Schoemaker</surname><given-names>RC</given-names></name>
<name><surname>Zuurman</surname><given-names>L</given-names></name><etal/>
</person-group>. (<year>2009</year>) <article-title>Central nervous system effects of alcohol at a pseudo-steady-state concentration using alcohol clamping in healthy volunteers</article-title>. <source>Br J Clin Pharmacol</source> <volume>68</volume>: <fpage>524</fpage>–<lpage>534</lpage>.</citation>
</ref>
<ref id="bibr67-0269881111431750">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Zoethout</surname><given-names>RW</given-names></name>
<name><surname>van Gerven</surname><given-names>JM</given-names></name>
<name><surname>Dumont</surname><given-names>GJ</given-names></name><etal/>
</person-group>. (<year>2008</year>) <article-title>A comparative study of two methods for attaining constant alcohol levels</article-title>. <source>Br J Clin Pharmacol</source> <volume>66</volume>: <fpage>674</fpage>–<lpage>681</lpage>.</citation>
</ref>
</ref-list>
</back>
</article>